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Extensive research have been conducted to dissect the rapidly evolving
mechanism of HIV-1 neuropathogenesis, and to investigate the viral
reservoirs in the central nervous system (CNS), which is considered as a
major barrier for the viral eradication. These efforts have been hindered due to
the paucity of relevant animal models of progressive HIV-1 brain infections.
Therefore, we developed a brand new mouse model reconstituted with
both a human immune system and human glia (primarily astrocyte and
oligodendrocyte

lineage)

in

the

brain.

We

transplanted

newborn

NOD/SCID/IL2Rγc−/− (NSG) mice with human neural progenitor cells (NPCs)
in the lateral ventricle and hematopoietic stem cells (HSCs) in the liver at
birth. Human astrocytes repopulated the white matter and periventricular
mouse brain regions in an anatomically symmetrical manner, with the highest
level of reconstitution in corpus callosum and periventricular region, and
relatively low levels in other regions like frontal cortex, striatum and brain
stem. Human glial engraftment induced transcriptional changes associated
with

multiple

biological

processes,

including

synaptic

transportation,

xii

angiogenesis, and axon growth, ion channel activities, compared to nonreconstituted mice, as determined by next generation RNA sequencing.
We then investigated the effects of HIV-1 infection on immune and glial
cells pathological and molecular changes. The immune analyses of these
HIV-1-infected mice showed increased meningeal and perivascular infiltration
by human HLA-DR+ cells and surveillance by activated immune cells in brain
tissue. The species-specific transcriptome analysis revealed alterations that
were linked to interferon (IFN) type 1 and 2 signaling pathways (STAT1, 2,
IRF9, MX1, ISG15, IFI6, CMPK2) and a range of host antiviral responses.
Differentially expressed mouse genes in the hippocampus reflected tissue
remodeling while down-regulated human genes were linked to altered cell
growth, glial cytoskeleton reorganization, oligodendrocyte differentiation and
myelin ensheathment (MBP, MOBP, PLP1, MAG and ZNF488). The results
overlapped with the disease profile observed by others in human HIV-1
encephalitic brains. Therefore, this new model provided a promising future for
study of human-specific viral-immune-glial interactions and discovery of new
therapeutic targets for HIV-1 nervous system infection.
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CHAPTER - 1
Introduction

2

1.1

HIV-associated

neurocognitive

disorders

(HAND)

and

the

neuropathogenesis of HIV-1 infection
The human immunodeficiency virus (HIV) is a member of retroviruses that
primarily infect human CD4+ T lymphocytes and macrophages. As the viral
replication persists, a progressive depletion of CD4+ T cells and the
consequent immune suppression render the hosts extreme vulnerability to
viral-induced tumors and opportunistic infections caused by bacteria, fungi,
parasites, and virus [1]. Antiretroviral therapies have been developed over the
last decade aiming at suppressing viral load and preserving immune function.
With the advent of combined antiretroviral therapies (cART), the mortality rates
in people infected with the HIV have been profoundly lowered, so has been the
frequency of drug resistance [2]. While this treatment has successfully reduced
the prevalence of AIDS and prolonged patients’ lifespans, so that HIV infection
is now primarily managed as a chronic disease [3], a serious comorbidity that
remains prevalent in nearly 30% of cART-treated HIV-infected individuals are
the HIV-associated neurocognitive disorders (HAND), a spectrum of
neurological

complications

that

range

from

asymptomatic

cognitive

impairments to severe dementia [4]. Although the severe cases of
HIV-associated dementia (HAD) are becoming increasingly uncommon with
the sustained suppression of peripheral viral load, milder forms of HAND
remain major concerns for HIV-infected individuals because of the persistent
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inflammation in the brain and the consequent impairment in their ability of
performing daily activities [5, 6]. In severe instances, HAND can contribute to
increased mortality in HIV-infected individuals because their cognitive
dysfunction results in cART noncompliance [7].
Several processes have been suggested to contribute to the pathogenesis
of HAND. These include: (1) Immune activation and viral infection of
mononuclear phagocytes (MPs) in the central nervous system (CNS),
including

microglia

and

macrophages,

create

a

pro-inflammatory

microenvironment, which imposes overwhelming stress signal upon neurons
and glia; (2) Neurotoxic viral products secreted by these brain MPs directly
cause neuronal damage and dropout; (3) co-existing factors such as aging,
drug

abuse,

Hepatitis

virus

B/C

(HBV/HCV)

co-infection,

and

low

socioeconomic status, also contribute to this devastating complication of HIV
disease. These mechanisms are discussed in detail below.

1.1.1 Immune activation and neuroinflammation
HIV infectious particles transport and immune cell migration across the BBB
are critical processes in HIV-induced CNS pathology. Mounting evidence has
shown HIV crosses the blood-brain barrier both as cell-free virus and using
infected macrophages as Trojan horses [8, 9]. It is widely recognized that in
the absence of a direct infection of neurons, indirect mechanisms play a major
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role in HAND neuronal dysfunctions and death. And indeed, the degree of
correlation between cognitive impairment and cerebrospinal fluid viral load are
not particularly robust, suggesting that the pathophysiology of HAND involves
more than just the immediate neurotoxicity of the virus.
HIV-infected macrophages and T cells not only infect brain resident cells
upon migration into the CNS, but also trigger a vigorous innate immune
response that drives the release of proinflammatory cytokines such as TNF-α,
IL-1β, and virotoxin-associated neurotoxic responses [10]. This process is
perpetuated by autocrine and paracrine amplification of cytokine activities and
activation of microglia and astrocytes, causing the release of more
inflammatory cytokines. In addition, chemokines such as CCL2 and CXCL8
released from infected MPs can further attract infiltration of infected
macrophages cross the blood-brain barrier (BBB). This autonomous
amplification of cytokine and chemokine cascades would eventually interrupt
astroglial function and integrity, compromising the metabolic function and
homeostasis of the CNS (Figure 1.1). In addition to the functions mentioned
above, astrocyte is a significant component of the BBB, ensuring the immune
privilege of the brain, which are altered in HAND patients. The impact of
astrocyte infection might be substantial because these cells demonstrate
aberrant intracellular signaling and abnormal interactions with the brain
endothelial cells of the BBB [11]. Reactive astrogliosis or astrocytes
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compromised by virus and inflammatory factors cannot consolidate BBB
properly, which would allow increased numbers of HIV-infected or activated
monocytes or lymphocytes to traffic into the perivascular space, thereby
exposing the brain to additional HIV-infected cells and proinflammatory insults.

1.1.2 Neurotoxic viral products
Another key process that mediates neurotoxicity is the release of soluble
neurotoxic viral proteins such as gp120, gp41, Tat, and Nef. As mentioned
above, activated MPs support a persistent viral infection and chronic
inflammation, serving as a major source of neurotoxic proteins that if produced
and accumulated in abundance, affect neuronal function. Studies of HIV gp120
transgenic mice indicated gp120 expression in astrocytes can lead to
microgliosis

and

astrogliosis

similar

to

that

seen

in

human

HIV

neuropathological findings [12]. Other studies also showed gp120 increased
BBB permeability, and therefore the infiltration of peripheral immune cells.
Furthermore, exposure to gp120 in vitro results in neuronal dendritic damage
and apoptosis of human primary neurons [13]. Other regulatory proteins of HIV
have also been found toxic to the CNS. In fact, mainstream cART regimens
inhibit HIV replication by targeting HIV protease or HIV reverse transcriptase.
Because of this, the drugs do not block production of the early viral proteins
Tat and Nef [14]. This is especially problematic for Tat because, despite of the
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presence of successful cART-mediated suppression of HIV replication,
infected cells still release Tat protein into the extracellular space where it can
exert neurotoxic effects by interacting with neighboring cells [15, 16]. Tat has
also been shown to interact with astrocytes and disrupt the tight junctions of
the BBB. As introduced in the previous paragraph, increased permeability of
the barrier can further augment neuroinflammation. Postmortem findings in
HIV patients brains with HAD showed expression of Nef in hippocampal
neurons, suggesting the role played by this protein in impairing hippocampal
neurons and consequent memory deficit in these patients [17]. It is reported
Nef leads to astroglial and neuronal cell death through both direct damage and
indirect induction of CXCL10 [18].

1.2 Brain microenvironment under homeostatic conditions
Brain microenvironment is closely monitored and regulated by different cellular
components in the CNS. Among them, astrocytes and microglia are the key
players. Astrocytes function as the pivot in maintaining CNS homeostasis,
regulating neurotransmitter release, stabilizing energy metabolism and forming
BBB. Additionally, emerging evidence is indicating that astrocytes participate
in the local innate immune responses mediated by a variety of receptors
involved in innate immunity, including Toll-like receptors, nucleotide-binding
oligomerization domains, double-stranded RNA-dependent protein kinase,
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scavenger receptors, mannose receptor and components of the complement
system [19]. Following activation, astrocytes are endowed with the ability to
secrete soluble mediators, such as CXCL10, CCL2, interleukin-6 and BAFF,
which have an impact on both innate and adaptive immune responses
[20]. Microglia are the local tissue macrophages governing local innate and
adaptive immune response, conducting immunosurveillance and scavenging
endogenous and exogenous risk factors in the CNS [21]. Recent studies also
suggest that microglia actively engulf synaptic material and play a major role in
synaptic pruning during postnatal neural development [22, 23]. These findings
imply microglia contribute to the synaptic maturation and the deficit of which
could

result

in

some

neurodevelopmental

disorders.

Other

cellular

components like pericytes and vascular endothelial cells also play critical roles
in maintaining the integrity of the BBB and regulating brain microenvironment
within a precisely confined limit.

1.3 Brain microenvironment altered by HIV-1 and other infectious agents
and endogenous damage1
Maintaining the central nervous system microenvironment after injury, infection,
inflammatory and degenerative diseases is contingent upon adequate control
1

Content in chapter 1.3 and 1.4 were reproduced with permission from Weizhe Li,

Hsin-I Tong,

Santhi Gorantla,

Larisa Y Poluektova,

Howard E Gendelman,

Yuanan Lu.

Neuropharmacologic Approaches to Restore the Brain’s Microenvironment; J Neuroimmune
Pharmacol. 2016, Jun 28; Copyright Springer.
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of glial homeostatic functions. Disease is caused by microbial, environmental
and endogenous factors that compromise ongoing nervous system functions.
The final result is neuronal injury, dropout and nerve connection loss, and
these underlie the pathobiology of Alzheimer’s and Parkinson’s disease,
amyotrophic lateral sclerosis, stroke, and bacterial, parasitic and viral
infections. However, what promotes disease are homeostatic changes in the
brain’s microenvironment affected by innate glial immune pro-inflammatory
and adaptive immune responses. These events disturb the brain’s metabolic
activities and communication abilities.
For infectious, degenerative and inflammatory disorders of the CNS,
microglial responses directly participate in disease. This occurs as a
consequence of the cells’ reaction to infectious, immune and degenerative
processes [24, 25]. First, viral infections, for example, can lead to a
parainfectious encephalomyelitis. This is commonly referred to as an acute
disseminated

encephalomyelitis

(ADEM)

where

disease

is

driven

pathobiologically by antigen-antibody attack. Autoimmunity occurs as a
consequence of generalized neuroinflammation in the brain and spinal
cord with profound myelin damage and white matter destruction. ADEM is
commonly triggered after infection with a spectrum of viruses that include, but
are not limited to influenza, measles, mumps, rubella, varicella zoster, Zika,
Epstein Bar, cytomegalo-, entero- and herpes simplex viruses. ADEM can also
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be driven by vaccinations [26, 27]. In both instances, brain injury is commonly
self-limited, and permanent neurological sequel can occur but not
commonly. Second, direct viral invasion of the CNS induces disease as a
consequence of productive infection in neurons or accessory glial or
endothelial cells. The process is active within the nervous system parenchyma.
Such invasion is dependent on the pathogen, the immune status of the host
and related genetics, and host immune responses. Such pathogenic events
are commonly associated with significant morbidity and mortality. The former
is seen with altered levels of consciousness and focal neurological symptoms
commonly include seizures [28]. A third cause of encephalitis is linked to
inflammatory responses that occur as a consequence of viral infection of
accessory cells and notably, monocytes, macrophages and microglia [8, 29].
This directly involves neuronal destructive activities induced by viral and
cellular neurotoxic proteins [30]. A singular example of accessory cell
infection-associated encephalitis is HIV-1 infection. Apropos of HIV, a vigorous
innate immune response occurs as a direct consequence of brain MP;
infection that drives pro-inflammatory and virotoxin-associated neurotoxic
responses [8, 10]. This is perpetuated by autocrine and paracrine amplification
of cytokine activities and by ongoing infection in the setting of a failure of
immune responses or in patients where antiretroviral therapy has not been
initiated [31]. Neuronal loss in HIV-1 encephalitis is strongly associated with
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synaptic and dendritic damage [32]. Overt synaptic loss is in turn linked to
severe cognitive impairment and brain viral load. Interestingly, levels of virus
can vary dependent on brain region and underlies that it is the inducer of
immune secretory factors, the perpetrators of disease [33]. Indeed, the
development of dementia commonly but not always is associated with virus
[34]. Interestingly, compensatory immune responses can restrict virus and
attenuate disease; also, the advent of combination antiretroviral therapy has
limited viral infection in the brain and facilitated host antiretroviral activities.
Nonetheless, given the limited penetrance of antiretroviral drugs across BBB
and comorbid conditions such as aging, drugs abuse and coinfection of
hepatitis

viruses

in

the

HIV-infected

population

[35],

persistent

neuroinflammation and viral reservoirs hiding in the brain remain to prevent the
CNS function from restoring [36, 37].
For the degenerative Alzheimer’s and Parkinson’s diseases (AD and PD), the
accumulation of misfolded, oxidized and aggregated proteins affect
neuroinflammation and rapidly lead to neuronal dysfunction [38-40]. Control of
disease can also be associated with inflammation and immunity but how this
occurs and can be harnessed for therapeutic gain is less clear [41, 42]. In
general terms, attenuation of inflammation either by drugs or by relevant
adaptive immune responses can facilitate disease outcomes, but the corollary
provides

opposite

endpoints.

Altogether,

with

the

importance

of
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neuroinflammation as a cause for a range of disorders of varying etiology, a
primary therapeutic goal is the control of brain’s microenvironment regardless
of the disease. Obviously, the removal of the root cause such as the infectious
agent or the misfolded proteins remains primary. This can be realized by
therapeutics and vaccination strategies [43-46]. However, what must follow is
the restoration of the brain’s innate immune function in sustaining its metabolic
function and homeostasis. This is what underlies restorative neuronal vitality
[47, 48].

1.4 Adjunctive strategies for restoration of brain homeostasis for HIV
infection of the brain
Here, we discuss the means to achieve the goals of controlling the brain’s
microenvironment. This will be highlighted through others and our own
developments of therapeutics that are aimed towards restoring neural
homeostasis. Underpinning this goal is a singular limitation that rests in drug
penetrance across the BBB and as such access of therapeutic agents to
damaged brain areas [49]. To this end, questions still exist on how BBB
disruption occurs and can be reversed, how altering vascular channels can
occur, and how chemical modification of drugs can be better developed to
maximize therapeutic delivery [50-52]. Although each approach has its
limitations and drawbacks, several chemical modifications of drugs to increase
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lipophilicity to move through lipophilic BBB, disguising them with lipophilic
molecules to make pro-drugs, attaching targeting molecules to get the drugs to
pass through the BBB, and packaging them into nanoparticles or exosomes
were investigated [53-55]. Yet another means rests in the delivery system
where we can harness MP as carriers of antiviral drug nanoparticles as well as
disease fighting proteins and nucleic acids [56]. The delivery of such agents
across the BBB remains a singular goal [57, 58]. Overall, we discuss the
feasibility of modulating the CNS microenvironment for therapeutic benefit. We
also reviewed the recent advances in delivery of therapeutic agents to the
brain with a particular emphasis on the means to restore the brain’s
microenvironment during disease using a spectrum of adjunctive therapies that
include those that attenuate inflammation and deliver growth factors to the
sites of injury [59-61].

1.4.1 Anti-inflammatory therapies
Neurodegenerative conditions like AD, PD and HAND are accompanied by
over active inflammatory responses that herald onset and tempo of disease
progression [42, 62]. The etiologies of each of these disorders reside in distinct
agents that include aggregation of misfolded protein, immune attack and viral
infection that lead to a commonly deleterious consequence that interrupts the
homeostasis of the local microenvironment. Microglia, a sensor and scavenger
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for pathological events in the CNS, become rapidly activated in response to
environmental, infectious and immunotoxin signals. These include in the case
of

neurodegenerative

diseases

with

misfolded

proteins.

Microglia

subsequently undergo a series of morphological, molecular and secretory
changes that affect the brain’s microenvironment [63, 64]. Additionally, the
interplay between microglia and astrocytes further polarizes the former
towards a neurotoxic phenotype [65]. Such changes in phenotype can affect
the brain’s microenvironment by producing a pro-inflammatory milieu that
speeds neuronal injury and ongoing disease pathogenesis [66]. Although the
CNS was historically considered to be immune-privileged, activation and
transformation of resident and circulating immune cells in pathogenesis of
neurodegenerative diseases indicate that brain hemostasis and immune
system status are tightly coupled. Evidence also suggests that there are
lymphoid controls operative in the brain [67]. Nonetheless, MP activation and
subsequent induction of chemokines like CCL2, CXCL8 and pro-inflammatory
mediators such as inducible nitric oxide synthase (iNOS), tumor necrosis
factor–α (TNF-α) and interleukin-6 (IL-6) collectively serve to speed the
infiltration of circulating immune cells into the CNS [68, 69] (Fig. 1.1). The
migration of effector memory T cells from the periphery generates
leukocyte-microglial crosstalk that exacerbates neuroinflammation and
restricts neuronal survival [56]. Another important player of immune origin
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contributing to the pro-inflammatory signals is mast cells, which are found in
most tissues; they transverse compromised BBB to become CNS residents.
Mast cell–glia communication also opens new perspectives for the
development of therapies targeting neuroinflammation by differentially
modulating activation of non-neuronal cells that normally control neuronal
sensitization

[70].

Immunopharmacologics

are

being

developed

as

neuroprotective strategies for disease either to block the attraction of the
circulating immune cells, T cells, macrophages and mast cells to the CNS by
restoring the BBB or to induce anti-inflammatory responses in the CNS [67].
Disease-modifying treatments can control inflammation and restore neural
function (Fig. 1.2, 1.3). Such adjunctive therapies take into account that
modulating both innate and adaptive immune responses are necessary for
success in ameliorating an inflammatory CNS microenvironment and as such
restore neuronal function during disease [71].
The pragmatic question that has been continuous over many years is why
have so many anti-inflammatory therapies failed to improve disease outcomes
for neurodegenerative disorders? [72]. This is believed to be due to the overall
pro-inflammatory microenvironment that remained uncontrolled or even
deteriorated as diseases progress, which counteracts the benefits from the
blockage of over-activated excitatory synapses. In this regard, comprehensive
management of neuroinflammation needs be taken at a more fundamental
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level. MP, microglia and macrophages, activated by HIV-1 facilitate
neuroinflammation

by

upregulating

pro-inflammatory

cytokines

and

monocyte-chemotaxis signals, which in turn further recruit circulating MP to the
diseased brain [73]. For example, for HAND, attempts were made to use
memantine, an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA)
receptor, as an adjunctive agent to antiretroviral therapies aimed at reducing
excitatory neurotoxicity, but if failed to improve cognitive functions [31]. This
was seen in a phase II double-blinded, randomized, placebo- controlled trial,
despite positive preclinical investigations [74].
Another example is with a mixed lineage kinase-3 (MLK3) inhibitor. MLK3,
a widely expressed kinase in neurons [75], astrocytes [76], microglia [77] and
myeloid lineage cells [78], regulates the c-Jun N-terminal Kinase (JNK) MAPK
and p38 signaling pathways, which is tightly related to monocyte chemotaxis
via CCL2 and CXCL8 and to cytokine production by microglia and brain
macrophages [79, 80]. It has been demonstrated that HIV Tat and gp120
protein can induce autophosphorylation at the activation loop of MLK3 in
primary rat neurons and human monocytes, which can be abolished by
CEP-1347, a large molecular inhibitor of MLK3 [81]. Further in vivo studies
also indicated the neuroprotective effect of CEP-1347 with apparent reduction
in microgliosis, neuronal loss and preserved dendritic integrity in an HIV
encephalitis (HIVE) model [60]. The neuroprotective attribute of CEP-1347 has
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also been shown in studies of other neurodegenerative disorders such as
Huntington’s disease [82, 83]. The promising results obtained in animal
models of neurodegenerative disorders stretched to CEP-1347 clinical trials in
PD patients. However, a phase II clinical trial concluded CEP-1347 as
ineffective treatment in early PD [84]. Symptoms of PD start when about 70–
80 % of striatal dopamine and about half of nigral dopamine neurons have
been lost [85]. Neuronal loss occurs generally over the course of a preclinical
period of several years [86]. Therefore, the irreversible degeneration may have
started before CEP-1347 could be given in this set of patients; moreover,
single neuroprotective agent may not be sufficient to reverse the disease
progression. Implementation of strategies for primary prevention will require
the identification of markers that would permit early diagnosis prior to the onset
of symptoms. Another concern resides in the limited distribution of CEP-1347
to the CNS due to its naturally polar structure and large molecular weight [87].
Indeed, a new MLK-3 inhibitor, URMC-099, with a favorable chemical profile
and CNS penetrant property was designed. This compound demonstrated a
significant amount of the neuroprotection imparted by inhibiting MLK3 in
immune cells and microglia [88].

1.4.2 Combination adjunctive and antiretroviral strategies
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The

effectiveness

of

CEP1347

and

URMC-099

in

the

control

of

neuroinflammation and protecting neurons from injury is significant with the
latter showing dramatic effects in the treatment of experimental HAND models
[60, 88]. The known etiology and definite onset point of HAND possibly render
this an advantage. Nevertheless, the power of these in vivo studies was
partially limited until very recently when URMC-099 was shown to have both
neuroprotective and unique antiretroviral effects [89]. Indeed, during studies to
extend the half-life of crystalline nanoformulated antiretroviral therapy
(nanoART), URMC-099, which was originally developed as an adjunctive
neuroprotective agent, was demonstrated to broaden antiviral responses and
improve ART biodistribution. Co-administration of long-acting ritonavir-boosted
atazanavir (nanoATV/r) nanoformulations with URMC-099 not only reduced
viral load and the numbers of HIV-1 infected CD4+ T-cells in lymphoid tissues
but sustained drug levels in reservoirs of viral infection. These results were
realized more than either drug alone when administered in infected humanized
NOD/SCID/IL2Rγc−/− mice and paralleled the formation of drug depots within
the reticuloendothelial system. The autophagosome appears to be that depot
and to lead to the sequestration of nanoATV/r in Rab-associated recycling and
late endosomes [89, 90]. These results provide an example for how unique
immune modulatory reactions can also improve antiretroviral responses. As
such the drug combinations are being developed beyond protease inhibitors to
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involve other drug classes that include integrase inhibitors to facilitate
cell-based viral clearance.

1.4.3 Cell-based gene and immune modulatory therapies
Well known is the fact that MP can cause BBB breakdown following brain
inflammation, migrating toward the inflammation site via processes known as
diapedesis and chemotaxis [91]. Relying on the natural inflammatory
responses, macrophages have been widely applied for the active delivery of
therapeutic agents, including nucleic acids, peptides, drugs and enzymes, to
the brain. Indeed, delivery of nanoART using macrophages as carriers has
significantly increased drug concentration and reduced HIV-1 replication in the
diseased compartments of HIVE rodents [92]. Limited effect on the ongoing
neuroinflammation in this study, however, reinforced the importance of
combining immune-modulatory therapy to restore the brain’s innate immune
and metabolic homeostasis.
Gene therapy is the therapeutic approach of precise manipulation of the
host genome, ultimately the function of targeted cells. Recent studies and
clinical trials have employed a variety of vehicles to deliver protective genes to
the CNS [93, 94] (NCT01446614, NCT01883661). With the known
effectiveness of soluble TNF-receptor (sTNFR) in the treatment of peripheral
autoimmune and inflammatory conditions including rheumatoid arthritis [95],
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we reasoned that a parallel approach could be applied for HIV infections of the
nervous system where a pro-inflammatory environment seen within the brain
incites neuronal-drop out and related cognitive dysfunction. We showed that
the bicistronic plasmid construct, sTNFR-Fc-eGFP, expressing the sTNFR-Fc
fusion protein and the green fluorescent protein (GFP) was suitable for stable
expression of sTNFR-Fc in human macrophages and neuronal cells as a
potential therapy for neuroAIDS [96]. To this end, we transduced bone
marrow-derived macrophages (BMDM) with the defective lentiviral vector
encoding sTNFR:Fc-eGFP (MOI =15). In BMDM sTNFR-GFP (below this used
as shorter abbreviation of transcript) was expressed with efficiency greater
than 45 % of transduced cells (Fig. 1.4a). The transduction efficiency of the
injected BMDM was confirmed by flow cytometry (ten days post transduction),
which demonstrated on average more than 45 % of BMDM were GFP+
(Fig. 1.4b). Two hours prior to adoptive transfer of the recombinant
sTNFR-GFP

transduced

BMDM,

deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)

the
mice

were

immune
injected

intracranially (i.c.) in the caudate putamen with 2 × 105 HIV-1ADA infected
monocyte-derived macrophages (MDM) as described previously [92]. This
procedure induced encephalitis referred to as HIVE, which paralleled what is
operative, in infected patients (Fig. 1.4c).
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Adoptive transfer of sTNFR transduced BMDM showed no change in
numbers of HIV-1p24 positive infected cells or the intensity of astrocyte
responses, but a modest reduction in microglial staining was evident
(Fig. 1.5a). In this survey histopathological analyses of brain sections were
acquired at sites of HIV-infection-mediated injury. Here, Iba-1 staining showed
that adoptive transfer of sTNFR-GFP transduced BMDM attenuated
microgliosis in brain areas surrounding the injection sites of HIV-1 infected
MDM, when compared to adoptive transfer of control BMDM. In Fig. 1.5b,
neurofilament staining was evaluated in and around the injection site and
quantitated by Nuance multispectral imaging system. Transduced HIV-1
infected mice have significantly higher NF content staining than control groups;
GFAP intensities were not significantly different amongst the groups (Fig. 1.5b,
lower panel). Parallel analyses of synaptic markers that include microtubule
associated protein 2 (MAP-2) and synaptophysin (SYN) failed to demonstrate
changes as a result of therapy and when quantitated by similar multispectral
imaging markers (data not shown).
We next evaluated by real-time polymerase chain reaction (RT-PCR) the
gene expression levels of sTNFR-Fc in the brain samples HIVE animals
injected with transduced BMDM; pro-inflammatory cytokine and neurotrophic
factor (GDNF and BDNF) expression levels were measured in brains of
animals that received sTNFR-Fc or control vector containing BMDM. Notably,
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expression of sTNFR-Fc was detected in the brains of animals that received
transduced BMDM (Fig. 1.5c). No statistically significant differences in NOS2,
IL-10, IL-1b, and TNF-α, BDNF and GDNF were noted between animals
treated with transduced (TD) and non-transduced (NTD) BMDM (Fig. 1.5e).
However, in these experiments measurement of pro- and anti- inflammatory
and neurotrophic factors were also compared in brain tissues of HIVE controls
(HIV-Ctl) with animals adoptively transferred with TD BMDM. Here, decreased
expression of NOS2, IL-10, IL-1b and TNF-α shown in the TD animals
compared to HIV-Ctl group (Fig. 1.5d). Adoptive transfer of macrophages in an
HIVE experimental model might have by itself negative effects associated with
additional influx of macrophages (with control vectors or non-transduced).
Delivery of sTNFR by transduced BMDM at the initiation of inflammation
showed positive anti-inflammatory effect. The reduction in microgliosis by
sTNFR-GFP transduced BMDM and the induction of anti-inflammatory milieu
might be contributing to the neuroprotective response with increased NF
immunostaining around the injected area (Fig.1.5b).
A similar approach has been applied in the PD study to deliver neurotropic
and protective factors to attenuate neuroinflammatory processes linked to
neuronal death [97]. Glial cell line–derived neurotrophic factor (GDNF) is the
most potent survival factor for the nigrostriatal dopaminergic neurons that
degenerate in PD [98, 99]. Current GDNF-based therapies have been
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seriously hindered by the difficulty in delivering these therapies to the brain.
Moreover, the progressive nature of PD requires continuous and sustained
delivery of GDNF over months or years in order to maintain dopamine neuron
survival and function. Conjugation of GDNF with other molecules enabling
BBB penetration may partially overcome these difficulties and increase the
feasibility of this approach for long-term sustained delivery of GDNF remains
uncertain. Advancement in the development of cell-based gene therapy that
can be applied systemically and achieve sustained release of moderate
amounts of GDNF opened a new window (Fig. 1.6). Adoptive transfer of
genetically modified macrophage expressing GDNF dramatically ameliorated
neuroinflammation and reduced degeneration of the tyrosine hydroxylase
positive (TH+) neurons of the substantia nigra and TH+ terminals in the striatum
of

the

1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine

(MPTP)

and

the

6-hydroxydopamine (6-OHDA) PD mice models [59, 97]. Genetically modified
macrophages acting as carriages for GDNF were recruited into the substantia
nigra of MPTP-treated mice, both the number of dopaminergic neurons and
the level of dopamine were rescued in the striatum of MPTP-treated GDNF
mice. In another study, exosomes released from GDNF-transfected
macrophages resulted in the drastic increase of neuronal maturation with a
pronounced outgrowth of axons and dendrites in PC12 neurons in vitro. This
attributes to the potential mechanism of efficient interactions between
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exosomal carriers and plasma membranes of dopaminergic neurons that
facilitate GDNF binding to their receptors, resulting in the profound therapeutic
effect. Nevertheless, due to the limited understanding, the mechanism
responsible for the therapeutic effects of cell-based GDNF delivery remains
inconclusive. Recently the hypothesis that growth factors could effectively
protect from endoplasmic reticulum stress, augment autophagy and brake or
significantly reduce speed of misfolded proteins accumulation in PD, HD, ALS
and AD was reviewed [100, 101]. A comprehensive examination and detailed
understanding of the mechanisms would be of great value in designing
strategies for cell-mediated drug delivery.
As inflammation has been implicated as a critical mechanism in AD
pathogenesis,

suppression

of

microglial

activation

and

subsequent

neuroinflammation was investigated employing several anti-inflammatory
drugs in trial, including natural nonsteroidal anti-inflammatory drugs (NSAIDs),
polyphenols and new drugs synthesized based on multi-target directed ligand
(MTDL) design [102]. TNF-alpha inhibitor administered perispinally in patients
with mild-to-severe AD showed promise as potential treatment approach [103].
Adjunctive therapies targeting multiple factors in AD processes might be the
best potential treatment strategy as in any other neurodegenerative disease.
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Figure 1.1. Neuroimmunological mechanisms for HAND. A vigorous innate
immune response occurs as a direct consequence of brain mononuclear
phagocytes (perivascular macrophages, microglia) infection that drives a
pro-inflammatory and virotoxin-associated neurotoxic response. This is
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perpetuated by an autonomous amplification of cytokine activities like TNF-α
and by a persistent chemotaxis of HIV-1 infected macrophages from periphery
in the setting of a failure of immune responses or an absence of antiretroviral
therapy. Meanwhile HIV-1 infected macrophages interrupt astroglial function
and integrity by pro-inflammatory mediators, compromising the metabolic
function and homeostasis of the CNS. Neuronal loss in HIV-1 encephalitis is
associated with synaptic and dendritic damage. Overt synaptic loss is in turn
linked to cognitive impairment induced by the brain’s viral load.
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Figure 1.2. Macrophage-based gene and immune modulatory therapies. The
chemokine gradient in diseased brain drives transduced macrophage
constitutively expressing sTNFR:Fc to the inflammatory site. Local release of
sTNFR:Fc reverses the pro-inflammatory microenvironment and blocks a cycle
of autocrine and paracrine cytokines produced by sequestering the major
pro-inflammatory mediator TNF-α.
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Figure 1.3. Combination of adjunctive and antiretroviral treatments for HAND.
Delivery of nanoART using macrophage as carriage serves to control HIV-1
replication in the brain by bringing antiretroviral drugs to local sites of viral
growth. The long-acting nanoformulated-antiretroviral medicines are in the
same subcellular viral compartment within multivesicular bodies (MVBs). This
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serves to reduce viral loads and numbers of peripheral HIV-1 infected CD4+
T-cells. Drug levels are sustained in reservoirs of viral infection. Upon the
suppression of persistent inflammation and clearance of viral brain reservoirs,
the function and homeostasis of microglia, astrocyte and most neurons are
maintained.
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Figure 1.4. Adoptive transplantation of sTNFR-GFP transduced BMDM into
HIVE mice. BMDM transduced with the sTNFR-GFP at day 7 in vitro were
shown positive for enhanced GFP expression and started to exhibit
macrophage-like branching appearance. One of three representative
experiments is shown (A). Transduction efficiency measured by flow cytometry
ten days post transduction demonstrated more than 45% transduced BMDM
were GFP+, one of three representative experiments is shown (B).
Four-week-old female NSG mice were stereotactically injected intracranially
into the caudate putamen with HIV-1ADA–infected MDM (2 × 105 cells in 5µl)
after 1 d of viral infection and referred to as HIVE mice (C). These mice were
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subsequently

transplanted

with

4×106

transduced

(TD,

n=12)

or

non-transduced (NTD, n=10) BMDMs in 200 µl PBS through tail vein. HIVE
controls (HIV-Ctl) were injected with same volume of PBS (n=8); SHAM
controls were only intracranially injected with 5 µl PBS (n=6). The mouse
sketch was provided by Encapsula NanoSciences with copyright permission.
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Figure 1.5. Delivery of sTNFR by transduced BMDM demonstrated an
anti-inflammatory effect in an HIVE model. Immunohistochemical staining of
HIV p24 protein identified HIV-1 infected human MDM at injection site.
Evaluation of astrogliosis and microgliosis by GFAP and Iba-1 staining
revealed adoptive transplantation of sTNFr:Fc-GFP transduced BMDM
attenuated

the

microgliosis

surrounding

injection

site

compared

to

transplantation of NTD cells. But no apparent reduction of astrogliosis was
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observed (A). GFAP/Neurofilament staining in the injection site were analyzed
by Nuance multispectral imaging system (20X objective). The representative
images are shown. Transduced group have significantly higher content of NF
(green) staining in comparison with other groups. However, the difference in
the intensity of GFAP was not statistically significant among groups (B). The
expression of genes encoding TNFR:Fc, NOS2, IL1-β, TNF-α , NOS2, BDNF,
and GDNF in brain subregions containing injection site were measured by
real-time RT-PCR using SYBR green system and specific primers. n=5 in TD
group, n=6 in NTD group, n=3 in HIV Ctl group. The expression of TNFR:Fc is
more than two-fold higher in TD than in NTD brain (C). The expression of
inflammatory cytokines including NOS2, IL-10, IL-1β, TNF-α and neurotrophic
factors like BDNF and GDNF, is lower in TD than they are in HIV-Ctl brain (D).
No significant differences in expression in TD group when compared to NTD
group were found (E). For multispectral image quantifications, images were
converted to 12 bit grayscale and quantified using ImagePro plus software.
There are 3 animals in each group, and 4 sections of selected regions from
each animal were analyzed and quantified. Each bar represented as mean ±
SEM, P values were obtained using one way ANOVA test, * p < 0.05.
Antibodies used include mouse anti-Neurofilament (1:200, Clone 2F11, Dako,
CA), polyclonal rabbit anti-GFAP (1:1000, Dako, CA), and rabbit anti- Iba1
(1:500, Wako, VA). For real-time RT-PCR, Ct values of each target gene were
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normalized to values for GAPDH in each sample. To calculate relative
amounts mRNA, the average Ct values were subtracted from GAPDH values
for each target gene to provide changes in Ct value. Fold Change in
expression was calculated as log2 relative units. Multiple t tests using
Holm-Sidak method were applied for statistical analysis. Each bar represent
mean ± SEM with *p < 0.05, **p < 0.01.
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Figure 1.6. Common mechanism of neurodegenerative pathology mediated
by microglia and astrocyte activation, and reversal of neuronal dropout by
introducing neurotrophic factors by transduced macrophages. Activated
microglia undergo a series of morphological, molecular and secretory changes
in the presence of abnormal proteins generated by neurons (a-synuclein,
amyloid etc.) that lead to a pro-inflammatory microenvironment in the CNS,
and, as results progressively increasing build-up of misfolded proteins. These
include the induction pro-inflammatory mediators such as IFN-g, NF-α and
IL-1β speeding the neuronal dysfunction and degeneration. The interplay
between microglia and astrocytes further impairs the astrocytes capability of
maintaining homeostasis and nourishing neurons with neurotrophic factors like
GDNF, BDNF, and NGF (A). Adoptive transfer of genetically modified
macrophage

expressing

neurotrophic

factors

dramatically

ameliorated
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neuroinflammation and reduced degeneration of neurons in rodent models of
AD and PD. Uptake of exosomes containing neurotrophic factors released
from transduced macrophages resulted in a reduction of misfolded protein
production via autophagy and should significantly delay their accumulation (B).
The efficient interactions between exosomal carriers and plasma membranes
of neurons that facilitate growth factor binding to their receptors may contribute
to therapeutic end points.
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CHAPTER - 2
Animal Models for NeuroAIDS
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2.1 Introduction
Since the emergence of HIV in humans in the 1980s, tremendous successes
have been achieved in restraining an infection, once considered fatal, into a
controllable illness with compliant affected individuals surviving for decades
with improved quality of life. During this journey, animal models offered
obvious advantages in the study of HIV/AIDS, allowing for a more invasive
investigation of the pathogenesis and for preclinical testing of drugs and
vaccines. Advances in humanized mouse models, non-human primate models,
and transgenic rodents, as well as recombinant challenge viruses have greatly
empower researchers in dissecting the pathological mechanisms, developing
novel antiretroviral therapies and vaccines, for the prevention and eradication
of HIV-infection.
As introduced in the previous chapter, the prevalence of milder forms of
HAND (e.g., asymptomatic neurocognitive impairment) have increased from
approximately 25 to 33%, despite of the extensive application of potent
antiretroviral therapy [6]. New challenges appear as to uncovering the
mechanisms by which the milder neurocognitive impairment persist in
HIV-infected individual regardless of effective suppression of plasma viral load.
Interestingly,

the

pathological

presentations

of

patients

with

milder

neurocognitive impairment also tend to be subtle, instead of dramatic changes
like infiltration of lymphocytes and virus that often observed in encephalitic
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patients. Therefore, more rigorous investigations into the underlying
pathophysiological mechanisms need to be carried out. Animal models will
continue to enable the study of HAND and testing of new therapeutic
approaches to combat them. Here we review the contributions of different
models to the understanding of HIV neuropathogenesis. While addressing the
limitations of currently available models, we propose a new mouse model that
readily reflects HIV neuropathogenesis in the era of cART.

2.2 Brain cells critical for HIV neuropathogenesis
In the chapter 1, we have reviewed the mechanisms involved in neuronal injury
during brain infection with HIV. Needless to say, damage to neurons would
eventually lead to impairment in neurocognitive performance. Among other
cellular

components

contributing

the

development

of

HAND,

brain

macrophages, microglia, and astrocytes are the key players.

2.2.1 Brain macrophages and microglia
The key cells that support productive HIV infection in the brain are
macrophages and microglia [8, 104]. However, distinctive from a traditional
view that microglia originated from bone marrow-derived monocytes that
circulate in the blood and enter the brain in non-pathological conditions and
during inflammation, recent population-based gene expression assays and
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fate-mapping studies revealed that microglia radically differ from brain
macrophages residing in perivascular and meningeal spaces in origins, fates,
and functions [105, 106].

Microglia derived from primitive hematopoiesis

that is spatiotemporally distinct from definitive hematopoiesis in fetal liver and
bone marrow, then migrate into neuroectoderm and distribute throughout the
CNS in later embryonic, fetal, and postnatal stages [107, 108]. While this topic
is out of the scope of this review, the distinction between microglia and brain
macrophages becomes extremely important when it comes to the questions of
repopulating mouse brains with human MPs-which progenitor population
should be chosen for the transplantation? Brain macrophages seem to be a
major target for the dissemination of HIV infection to the brain from the
periphery. Interestingly, it has been shown that HIV-infected monocytes can
cross the BBB more readily than uninfected monocytes [109]. These findings
are informative for the application of humanized mouse models to recapitulate
MP mediated viral entry and neuroinflammation [110]. Meanwhile, microglia
are equally important target of HIV infection, and are recognized as a potential
viral reservoir in the CNS, posing a barrier for viral eradication. However, the
establishment of a rodent model carrying human microglia has been hindered
due to an insufficiency of knowledge in the precise identity of microglial
precursors and an absence of optimal mouse platforms to support the survival
and development of human microglia.
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2.2.2 Astrocytes
Perivascular astrocytes are another cell receiving increasing attention as an
important reservoir for HIV [37, 111]. Previous studies showed that, in
individuals with HAND, as many as 19% of the perivascular astrocytes are
infected with HIV [111]. However, it is inaccurate to state that the HIV-1 DNA
detected

in

3-19%

astrocytes

from

autopsy

brain

tissues

were

replication-competent proviral DNA. Due to the ex-vivo nature [111, 112], the
original studies were not able to conclude if the nearly 20% astrocytes are true
infections or restricted infections. According to decades of research, infection
of astrocytes by HIV is highly restricted [113]. On one hand, the restricted
infections stem from insufficient receptor-medicated viral entry due to a lack of
necessary receptors. On the other hand, restrictions were also noted in viral
replication and assembly, which are majorly induced by type 1 interferon
receptor activation and signaling. However, astrocyte adsorption and uptake of
cell-free virus particles via endocytosis-mediated viral entry would lead to
detection of infectious viral nucleic acids in cultures or ex vivo analyzed
astrocytes [114, 115]. Additionally, astrocyte engulfment of HIV-1 infected
permissive cells like macrophages and lymphocytes or their subcellular
components would also lead to detection of astrocyte-associated viral proteins
and nucleic acids that could be mistaken for infection [116]. Therefore, it is
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very imprudent to equate detection of viral materials to the productive infection
of astrocytes.
But controversy still remains regarding whether astrocytes would be likely
to serve as viral reservoirs. Also, the possibility cannot be excluded that
astrocytes in situ exposed to the neural tissue environment may be induced to
express CD4 and CCR5, and therefore be susceptible to HIV-1 infection.
Because astrocytes outnumber neurons by 10:1, this could represent a large
amount of infection in the brain, which was previously under-recognized.

2.3 Non-human primate model
As non-natural SIV hosts, Asian macaques have become the most common
and widely accepted models for HIV/AIDS pathogenesis and latency. Studies
on HIV-neuropathogenesis have been extensively paralleled in SIV-infected
rhesus macaque models. However, disease progresses more rapidly in
SIV-infected macaques than in HIV-infected humans, typically 1-2 years to
AIDS in SIV-infected animals compared to 8-10 years in humans, if not
receiving antiretroviral therapies [117]. Although later stages of the disease
have been investigated in detail where pathology of encephalitis is apparent as
a result of the activation of virus-infected mononuclear phagocytes and
lymphocyte infiltration, the pathophysiological alterations at early stages after
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acute infection remain largely unknown in this model. Additionally, it is costly
to work with these large animal models.

2.4 HIV transgenic rodent model
The cost of working with non-human primate model restricts them from being
broadly used. To this end, a cost-effective small animal model is more
practically acceptable. Since the well-established methods for manipulating
the mouse and rat genome provided researchers a larger extent of flexibility in
dissecting the roles of specific factors in a pathological process, rodent models
play increasingly important role in HAND research. Because HIV is not
infectious to rodents, efforts have been made using genetic techniques to
circumvent the species-specificity of the virus to create rodents to mimic
human pathology.
One approach was to express human receptor and co-receptors
necessary for viral entry, such as CD4, CCR5, and CXCR4, on the surface of
murine cells [118]. This is based on the rationale that the restriction on viral
entry imposed by species-specific receptors prevents murine cells from being
effective infected by HIV. This theoretic cornerstone was soon proved unsound.
Although these mouse models support viral entry, the primary barrier to HIV
infectivity in mouse is that the cells are unable to support HIV replication. This
is due to the intrinsic restrictions imposed by a series of restrictive factors,
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such as TRIM5a, APOBEC3, SAMHD, that prevent viral integration into the
mouse genome and subsequent viral production [119, 120]. Alternative efforts
made on engineering viral structures, for instance replacing gp120 to a murine
cells tropic gp80, also failed to establish HIV replication and progression [121].
Additionally, models selectively expressing viral accessary or regulatory
proteins in specific type of cells have also been broadly applied to investigate
the effect of these proteins on neuroinflammation [122, 123]. This approach
is to genetically engineer rodents to express non-infectious provirus, with
deletion of gag and pol genes. The transgenic rodent models do not focus on
the infection, but on the effect of accessory and regulatory viral proteins in
neuroinflammation. As reviewed in the previous chapter, these proteins,
including gp120, Nef and Tat can exert neurotoxicity by direct action on
neurons and by producing inflammation via inducing cytokine production in the
periphery and CNS [124]. Although infection results in an adaptive
inflammatory response, inflammation can also emerge independent of
infection, and chronic inflammation can lead to neurodegenerative disorders
[125]. HIV-1 transgenic rats showed significantly higher mRNA and protein
levels of the inflammatory cytokines, IL-1β and TNF-α, as well as a decrease in
the neuroprotective brain-derived neurotrophic factor (BDNF), among other
changes in regulatory factors and signaling [126]. Similarly, another study
determined that pro-inflammatory cytokines, such as IFN-γ, TNF-α, and IL-1β,
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are up-regulated in the HIV-1 transgenic rat, which is in part responsible for the
neurodegeneration seen in HIV-infected individuals [127].
Evidence from studies employing different experimental strategies strongly
support the hypothesis that viral proteins produce toxic effects that cause
neuroinflammation and neurological dysfunction. The viral protein gp120 binds
to the chemokine receptor, CXCR4, an HIV-1 co-receptor involved in AIDS,
that is also expressed in neural progenitor cells to guide brain development
[128]. Gp120 stimulates CXCR4 and activates pro-apoptotic pathways in
human neuroblastoma cells [129]. Gp120 also induces apoptosis through its
interaction with the CCR5 receptor [130]. The transgenic mice that contain
astrocytes expressing gp120 under the control of the promoter of glial fibrillary
acidic

protein

(GFAP)

developed

CNS

damage

consistent

with

HIV-1-associated neuropathology [12].
The supplementary HIV-1 proteins also produce neurotoxicity. Tat is one
of the proteins produced by HIV following early infection. Even in the absence
of viral replication, a large amount of Tat protein can be produced and secreted.
Transgenic mouse lines that express Tat protein using GFAP promoter in
either constitutive or inducible manners were created to understand the
contribution of Tat protein to the HIV neuropathogenesis [131, 132]. Similar to
gp120

transgenic

animals,

Tat

transgenic

mice

demonstrated

neuropathological changes. Subsequent studies linked the neurotoxicity of Tat
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to its pro-apoptotic effect via excessively stimulating NMDA receptors, and by
interacting with the low-density lipoprotein (LDL) receptor gene family
expressed in neurons and astrocytes [133, 134]. Changes in neuronal circuitry
also occur in response to the presence of Tat and, as do deficits in learning
and memory following exogenous Tat as well as endogenously expressed Tat
[135]. Other viral proteins, such as Nef Vpr and Vpu, have also been
demonstrated with neurotoxic effects, producing inflammatory cytokines, and
affecting CNS function and behavior, including memory performance of
standard learning tasks [136-138]
While the transgenic rodent models are suitable for elucidating the
mechanisms underlying impairment in neurocognitive function caused by the
accumulation of viral gene products, they are not helpful for examining the
initial infection with HIV and the progression of the disease from a perspective
that the virus interacts with immune and neural networks as an integral entity.
Another caveat is that they are not suitable for studying the impact of cART on
viral replication, though many adjunctive therapeutic approaches have been
developed and tested using such platforms. Moreover, the significance of
many studies using transgenic mouse models to examine the impairment in
cognition and memory are undermined by the fact that most these behaviors
studies were initially designed for rat and interspecies differences do exist
regarding spacial learning and task memory [139].
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2.5 Humanized model
Generally, humanized mouse refers to a mouse carrying functioning human
cells, tissues, and organs. However, with our focus on models for studying HIV
neuropathogenesis, we limit the scope of this review to mouse models
reconstituted with human immune and nervous systems and their applications
in understanding pathological processes and in developing therapeutics.

2.5.1 The HIV encephalitis mouse model
Historically, HIV-encephalitis characterized by infiltration of infected MPs and
active viral replication in the brain, correlates to a rapid decline in
neurocognitive functions in the pre-cART era [140]. Therefore, the first
attempts to reflect the pathogenesis of HIV encephalitis (HIVE) was performed
by injecting MPs that are infected with a macrophage-tropic strain of HIV-1
(HIV-1ADA) into the brain of immunodeficient mice [141]. These infected cells
were stereotaxically injected into the basal ganglia, putamen or cortex [142].
Following implantation, these mice exhibited histopathological features
paralleling those observed in human HIVE, including expression of HIV p24
antigen in the infected macrophages, the formation of multinucleated giant
cells, astrocytosis, microglial activation and neuronal cell death. Subsequent
efforts were made to assess neuronal function in the HIVE model using a
range of behavioral and functional tests. Mice injected with MDMs developed
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cognitive impairments and associated synaptic dysfunctions [143-145]. This
mouse model has also been used extensively for evaluating new antiretroviral
and adjunctive therapeutics as well as delivery systems for HIVE. Various
antiretroviral strategies were assessed to maximize drug-brain delivery and to
reduce HIV-1 replication within the brain in HIVE mice [92, 146, 147]. As
previously mentioned, because activation of MPs by HIV infection can further
induced

an

autonomously

affects synaptic plasticity

and

amplified

neuronal

inflammation

development

in

that

HIV-infected

individuals, much research effort has been focused on the discovery and
design of neuroprotective compounds as adjunctive therapies to cART. The
HIVE mouse model has also been proved to be useful for screening potential
neuroprotective compounds [60, 148, 149].
Despite the enormous contributions of HIVE model to the study of
neuroAIDS, it seems unable to reflect the rapidly evolving face of HIV
neuropathogenesis in the era of cART, since the noticeable pathology of HIV
encephalitis becomes rare in the well-treated patients. Moreover, traumatic
injury resulting from stereotaxic injection may confound the traumatic brain
injury with infection-induced injury, making it hard to interpret the experimental
results. Finally, the average 2-5 weeks period of active infection and
inflammatory responses makes this model unable to mimic chronic infection.
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2.5.2 Human immune system reconstituted model
Previous models cannot fulfill the goal of establishing a model system that can
sustain long-term chronic HIV infection to investigate the ongoing interactions
of peripheral infections to brain immune cell ingress, neuroinflammation and
resulting neurodegeneration. This was made possible by the development of
mouse strains with severe defects in both innate and adaptive immunity.
These include the partial deletion of common cytokine receptor γ chain (γc–/–,
or interleukin-2

receptor γc)

on

a

NOD/ShiJic-scid (NOG)

mouse

background and a complete deletion of γcnull on NOD/LtSz-scid (NSG) mouse,
as well as the BALB/cRag2–/–γc–/– (BRG) mouse. Humanized mouse models
have been established in the NOG, NSG, and BRG mice by intrahepatic
administration of CD34+ hematopoietic stem cells (HSC model) into newborn
pups, or by surgical transplantation of human fetal liver and thymus tissue
fragments followed by intravenous injection of human fetal liver-derived
CD34+ HSC (BLT model). Although the BLT mouse model has been
extensively used to investigate important aspects of HIV-associated pathology,
transmission, prevention, and more recently HIV persistence [150-152], this
model has not been used for studies of HIV infection of the CNS. Therefore,
we will only review the applications of the HSC model in the studies of
NeuroAIDS in the following paragraphs.
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The long-term immune reconstitution of NOG/NSG mice by human HSCs
provides a new approach to study HAND. The major characteristics of chimeric
animals are stable human hematopoiesis in mouse bone marrow, occupancy
of the murine thymus with human thymocytes and their maturation into T
cell subsets, complete reconstitution of murine peripheral lymphoid organs
including lymph nodes and spleen, as well as gut-associated lymphoid tissue
(GALT), and the infiltration of human macrophages throughout brain
parenchyma, the meningeal and perivascular spaces [153-156]. These human
immune system reconstituted mice support chronic HIV-1 replication and
recapitulate the course of viral replication, with loss of CD4+ T cells and the
development of HIV-1-specific cellular and humoral immune responses [157,
158]. It was also found systemic HIV infection accelerated the entry of
peripheral human immune cells into the brain [154]. Viruses were thereby
disseminated throughout the brain as the peripheral infected cells infiltrated.
Astrogliosis and microglial activation, as well as neuronal injury, were
commonly seen, and neurodegeneration was found to correlate with peripheral
viral load and CD4+ cell depletion [53]. The development of meningitis, and
more rarely meningoencephalitis, was observed [154]. These findings, taken
together, suggested natural HIV-1 progression within the CNS of human
immune system reconstituted mice.
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Considerable studies have been carried out on humanized mouse models
to test the efficacy and safety of cART and neutralizing antibodies, given its
ability to sustain a long-term viral replication [159, 160]. Nevertheless, there
are very few reports on the effects of these therapies on the neuropathology of
HIV infected mice. It is probably due to the low tissue distribution of regular
cART to the brain [161]. Recently, one study demonstrated the long-acting
nanoART elicited neuroprotective responses with remarkable reversal of
synaptic injury when compared to untreated virus-infected animals [162],
suggesting such long-acting nanoART has improved brain delivery, sustained
and targeted efficacy and with limited systemic toxicities. Such findings also
strongly suggest that the humanized mouse model is likely to be a valuable
tool

for

evaluating

the

targeting

delivery

and

efficacy

of

long-acting antiretroviral drugs.

2.6 Humanization of mouse brain and future directions
Although the HIV-infected humanized mouse models have been characterized
extensively for their ability to recapitulate the human immune response against
HIV, and been applied widely to test the efficacy of therapeutic approaches,
they are insufficient to assess HIV-associated neuropathology and related
neurocognitive dysfunctions. In 2012, Laura B. Jaeger and Avindra Nath
discussed the possibility of establishing a new mouse models with combined
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human immune system and brain cells (primarily microglia and astrocytes)
reconstitution to study HIV neuropathogenesis [163]. The advantage of such
a chimeric mouse model is that both the transplanted human lymphoid and
brain tissue will be permissive to HIV infection, thereby enable the study of
neuropathological mechanisms that contribute to the development of HAND in
one physiological setting. Since microglia and astrocytes are considered to be
potential viral reservoirs in the CNS, such model will also be valuable in
investigating viral reservoirs and in developing strategies for eradication. But
due to time limits, this review only summarized studies engaged in
humanization of mouse brains published before 2012, including those studies
have successfully implanted different brain cells into the mouse brain, such as
neurons, oligodenrocytes, and neuroprogenitors cells, but not astrocytes and
microglia [164-167]. However, recent studies demonstrated the engraftment of
mouse brain with A2B5+/PSNCAM- glial progenitors generating a chimeric
mouse brain primarily reconstituted with human astrocytes [168, 169].
Previous work also showed transplantation of human neural progenitor cells
(NPC) in an ischemic or traumatically injured rat brain are capable of
differentiating into cells bearing neuronal markers with only limited numbers of
GFAP+ cells at the injured brain margins [170]. From these studies, it has been
shown that early transplantation is essential for achieving maximum migration
of human glial cells in the mouse brain [171, 172]. These studies, taken
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together, confirmed the feasibility of establishing a human immune
system-glial dual reconstituted mouse model.
Regarding the reconstitution of human microglia, which is another player in
HIV infection of the CNS and an important viral reservoirs, continued efforts
need to be made to identify the human microglial progenitors during primitive
hematopoiesis, and to generate a mouse brain microenvironment permissive
to human microglial survival and development. As reviewed in the previous
paragraph, recent fate-mapping and gene expression profiling studies
revealed that microglia originate from primitive stem cells in the yolk sac at the
early stage of embryogenesis, and not from hematopoietic stem cells in the
bone marrow, nor from neuroectoderm which gives rise to neurons, astrocytes
and oliodendrocytes as well as ependymal cells [105, 108, 173]. They then
migrate into to neuroectoderm and distribute throughout the CNS in the later
embryonic, fetal, and postnatal stages. During the development of microglia,
colony-stimulating factor-1 (CSF1) was initially found to provide survival signal
for developing microglia. However, later it was found microglia are more
profoundly affected by the absence of CSF-1 receptor (CSF1R) than by CSF1.
A second CSF1R ligand, interleukin-34 (IL-34) was identified later, and has
been shown to be highly expressed by neurons and play a critical role in
microglial survival and differentiation [174, 175]. These findings are informative
for the future efforts to genetically engineer a mouse strain expressing IL-34 in
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the brain to provide a permissive microenvironment for human microglia
engraftment.
Finally, these immune-CNS dual reconstituted models would be remarkably
useful for detection of biomarkers that could be used to assess
presymptomatic neurologic changes caused by HIV infection.
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CHAPTER - 3
Combinatorial Brain and Blood Humanized Mouse
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3.1 Abstract
Studies

of

innate

glial

cell

responses

after

progressive

human

immunodeficiency virus type one (HIV-1) infection are hindered due to the
paucity of relevant small-animal models of human disease. To overcome this
limitation, a mouse model with dual humanized brain and immune system was
created. We transplanted newborn NSG mice both with human neuroglial
progenitor cells (NPCs) and hematopoietic stem cells (HSCs). This
experimental approach resulted in human astrocyte and oligodendrocyte
repopulation in anatomically symmetrical white matter and periventricular
mouse brain regions. RNA sequencing was applied to examine the influence of
human cells engraftment on the mouse transcriptional profile in selected brain
regions. Glial humanization of mouse brain with a human peripheral immune
system induced modest, yet extensive, transcriptional changes associated
with

multiple

biological

processes,

including

synaptic

transportation,

angiogenesis, axon growth, ion channel activities.

3.2 Introduction
Despite sustained investigation of the pathophysiological mechanisms of
HAND, virus-induced neuroimmune communications are not well understood
[176, 177]. As the virus cannot infect rodent cells, disease conditions that
cause immune, glial, and neural cell dysfunctions cannot be mirrored in any
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small animal. Transgenic mice containing the whole viral genome or
individually expressed proteins and the brains of animals injected with viral
proteins or human infected cells reflect only disease components [178].
Lentiviral infections of non-human primates, cats, and ungulates do replicate
HIV nervous system comorbidities [179], but show broad gaps in mirroring
natural infectious processes [180]. This can also be argued with mice who
possess a self-sustainable humanized immune system. These humanized
animals are susceptible to HIV infection and support persistent replication of
virus, but resultant structural and functional changes to the brain are limited
[181-183]. The absence of human glial cells and differences in responses to
the virus, between species, combined with functional system complexities limit
mechanistic studies [184].
As the most abundant cell types in the human central nervous system,
astrocytes and oligodendrocytes, have pivotal roles in brain homeostasis and
metabolism. Astrocytes are limited in their susceptibility to HIV infection [185,
186] and they are abortively infected [187]. In contrast, oligodendrocytes,
which produce myelin, are not vulnerable to HIV infection. During disease,
communication between astrocytes and infected mononuclear phagocytes
(MP; monocyte macrophages and microglia) herald changes in the brain’s
pro-inflammatory microenvironment. Amongst each of these cells, except for
MP and CD4 T cells, multiple intracellular restrictions exist. For example, viral
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receptors, absent on the cell surface of astrocytes, are operative on MP, which
leads to differential abilities of the virus to complete its life cycle [188, 189].
The interactions between lymphocytes and monocytes that traffic into the
nervous system drive glial activation during progressive viral infection [190].
Thus, if a disease model can accurately replicate the complex features of an
infection of the nervous system, in a single physiological system, it must
contain both a human immune and glial elements [178]. To such ends, we
established a dual reconstituted mouse model that incorporates human
lymphocytes, monocytes and glia. Glial humanization of mouse brain with a
human

peripheral

immune

system

induced

modest

yet

extensive

transcriptional changes associated with multiple biological processes. The
importance of this model is underscored by ability to study specific glial
transcriptional signatures that closely mirror human disease [176].

3.3 Results
3.3.1 Human brain cell transplantation
Mice were reconstituted with human hematolymphoid tissues and glial cells.
Newborn irradiated NSG mice were transplanted intracranially with human
NPCs and intrahepatically with cluster of differentiation 34 (CD34)+ HSC from
the same donor (Fig. 3.1A, Table 3.3). NPCs were isolated from fetal human
brains to generate neurospheres, from which single cell suspension was
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prepared and transplanted at 105 cells per mouse (Fig 3.1B). The lineage
potential of the NPCs were investigated in short-term cultures. Mixtures of
neural lineage cells arising from parental progenitors included glial fibrillary
acidic protein (GFAP)/microtubule-associated protein (MAP) glial progenitors,
nestin/GFAP neural progenitors with radial glia characteristics, glutamic acid
decarboxylase 67 (GAD67) and class III β-tubulin (Tuj-1)+ neuronal lineage
cells (Fig 3.1C). These data indicated that the NPCs derived from fetal brains
retained multi-lineage competence.
Glial cells were stimulated and neuronal differentiation limited by exposure
of NPCs to escalating concentrations of fibroblast growth factor prior to
intraventricular cell transplantation. The fate and distribution of the human
NPCs in mouse brain were then evaluated at 6 months of age (Fig. 3.2).
Human glial were found equally across both hemispheres with distributions in
the corpus callosum (CC), striatum (Str), cerebellum (CB) and periventricular
areas (Fig. 3.2 A). A large proportion of the human cells in mouse brains were
GFAP positive with typical astrocyte morphology based on size and process.
Human astrocytes commonly replaced their murine counterparts with nearly
70–80% occupancy. This was seen in fields of view that included the CC and
Str. There was limited occupancy of human astrocytes in the frontal cortex
(FC) and CB (Fig 3.2 C). Surprisingly, nearly 40% of human astrocytes in the
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CC and 20–30% in the hippocampus (Hip) and Str were Olig2+, an
oligodendrocyte-identifying marker (Fig 3.2 B and D).

3.3.2 Peripheral hematolymphoid humanization
A human peripheral hemato-lymphoid system was established in the NSG
mice (Fig 3.3, Table 3.3) [182]. Flow cytometric analyses of the peripheral
blood of humanized mice at 24 weeks of age showed that among human
CD45+ cells, B (CD19+) and T lymphocytes (CD3+) were present (Fig 3.3 A).
CD4+ T lymphocyte population was four times that of CD8+ cytotoxic T cells
(Fig 3.3 B). The CD14+ monocyte population was approximately 1% of the total
CD45+ cells. Human hematopoiesis was sustained in the bone marrow as
seen by the presence of CD34+ HSC and CD33+ myeloid lineage precursor
cells [191, 192]. In the brain, human peripheral blood leukocytes infiltrated the
meningeal and perivascular spaces, the olfactory bulb and the cortex. The
majority of HLA-DR cells were located in the meningeal space, with fewer
numbers in the perivascular space and brain parenchyma (Fig 3.3 C and D).
Among these, the majority were CD163+ macrophages, and some showed
branching appearances. Less than 20% of HLA-DR cells were CD4+, and 9%
were CD8+ T lymphocytes (Fig 3.3 C and E).

3.3.3 Transcriptional changes in the humanized mouse brain
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To assess the biological outcomes of peripheral immune and brain
humanization, we applied deep sequencing to assess transcriptional profiles
seen as a consequence of glia-immune crosstalk. We selected three infected
animals with similar patterns of human immune cell repopulation, astrocyte
distribution and peripheral viral loads for study. Three equivalent aged NSG
uninfected mice served as controls (Fig 4.2 A). Hip and CC repopulated by
human glial cells were dissected for sequencing (Fig 4.2 C). All sequenced
reads (~100 bp length) were aligned to the mouse database (University of
California Santa Cruz Genome Browser database, GRCm38/mm10). The
experiment was designed to search for differentially expressed mouse
transcripts as a result of human cell engraftment and HIV-1-infection.
Subsequently, the reads unmapped to the mouse genome were re-aligned to
the human genome (GRCh38/hg19) to find human specific transcriptional
changes. The overall mapped mm10 reads average ratio was 92% for all 9 Hip
samples and 94% for all 9 CC samples (Table 3.2).

3.3.4 Region-specific alterations of mouse transcriptom by engrafted
human glial cells
We used GeneCards® integrative database to obtain categorized results for
differentially expressed mouse genes. This was done to identify Gene
Ontology (GO) gene sets related to mouse brain humanization. The obtained
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information about the biological roles of the genes of interest we summarized
in Fig 3.4. Glial humanization of mouse brain with a human peripheral immune
system induced modest, yet extensive, transcriptional changes associated
with multiple biological processes, including synaptic transportation (C1QL2),
regulation of neural progenitor cell proliferation (RASL10A), angiogenesis
(DCN, ENPP2), axon growth (SERPINI1), ion channel activities (SLC8A2),
learning and memory, aging (Fig 3.4).

3.4 Discussion
We created a unique mouse model that contains both a human immune
system and human glial cells in the brain, which will allow us to investigate the
neural-immune interactions during progressive HIV infection and the reservoirs
in the CNS.
We confirmed that NPC can differentiate into multiple neural lineages,
including neurons, astrocytes, and oligodendrocytes [193]. Previous work
demonstrated that transplantation of human neurosphere-derived NPC can
occur in a living mouse with viable human-derived neurons and glial cells [194,
195]. Moreover, transplantation of hu-NPC in an ischemic or traumatically
injured rat brain are capable of differentiating into cells bearing neuronal
markers with only limited numbers of astrocytes present at the injured brain
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margins [170]. Nonetheless, early transplantation is essential to optimize
migration responses of human glia in mouse brains [171, 172].
We showed that human NPC transplanted into immunodeficient NSG mice
at an early postnatal age (P1) demonstrated a broad glial distribution pattern.
By 6 months of age, a large number of human astrocytes repopulated multiple
regions along whiter matter tracts. Surprisingly, these cells derived from
hu-NPC, readily replaced their murine counterparts. This was seen in selected
regions such as CC and striatum (Fig 3.2 A and B). We also found a
considerable number of human cells positive for Olig2 (Fig 3.2 C and D), a
determining

factor

for

oligodendrocyte

differentiation.

Glial-biased

differentiation seen in our humanized brains can be explained in two ways.
The in situ fate of NPC is restricted by the local white-matter environment
[196]. The molecular signals in the recipient white matter may provide the
migration route for human cells and facilitate a glia-oriented fate, possibly
without any exogenous influence. Second, a fundamental feature of brain
development is that neurons can be generated before glia [197]. Expansion of
these neural progenitor cells in the presence of fibroblast growth factor (FGF)
and leukemia inhibitory factor (LIF) may drive these cells toward a stage where
glial bias is increased with concomitant loss of neurogenic potential [198].
Interestingly, human glial engraftment induced a broad range of changes
in the mouse transcriptional profile. The mouse genes relate to biological
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process including synaptic transportation, angiogenesis, axon growth, ion
transport, learning or memory were found modestly up-regulated (Fig 3.4).
Although it is hard to precisely predict the consequence of human glia
engraftment on mouse brain structure and neurological function at this stage,
previous studies indeed demonstrated human astrocytes possess higher
structural complexity and functional capacity than their murine counterparts
[199], and engraftment of human glia differentially enhance both long-term
potentiation and learning in mice [169].
The broad repopulation of human astrocytes as well as increased
infiltration of peripheral immune cells in the brain of dual reconstituted mouse
also provide us a promising opportunity to investigate the role of astrocytes in
progressive viral infection.
In summary, we were able to successfully engraft neonatal NSG mice with
NPCs and HSCs. The dual reconstituted chimeric mouse model contained
both a human immune system and human glia. This model allowed us to
investigate how glial-immunocyte crosstalk is affected by HIV-1 infection.
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Figure 3.1. Generation of dual reconstituted mice and properties of neural
progenitor cells (NPCs). (A) Scheme of the transplantation of human blood
and brain progenitors at birth and the period of observation. Humanization of
bone marrow and secondary lymphoid tissues are shown in red. Humanization
of brain (blue with yellow dots) is shown by enlarged view of sagittal section
(1×) stained for human-specific cytoplasmic marker by STEM121 antibodies
(Takara Bio USA). (B) Example of neurosphere in culture. Image obtained by a
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Nikon TE300 microscope (Nikon Instruments, Inc., Melville, NY, USA) at
original magnification of 200×. (C) Representative immunofluorescent images
of 48-hour cultured single cells derived from neurospheres. Upper line panels
show cells positive for glial fibrillary acidic protein (GFAP, green) and nestin
(red), both known as progenitor cells with radial glia characteristics. Middle line
panels demonstrate cells stained by microtubule-associated protein 2 (MAP2;
green) and GFAP (red) antibodies, which are considered to be early stage glial
precursors. Lower line panels show cells positively stained by the neuronal
marker glutamic acid decarboxylase 67 (GAD67; green) and class III β-tubulin
(Tuj-1; red). Original images were captured by a Zeiss LSM510 system (Carl
Zeiss Microscopy GmbH, Jena, Germany) with 400× magnification. Bar = 50
µm. Two independent staining experiments were performed.

67

68

Figure 3.2. Glial humanization of the mouse brain. (A) Animals were analyzed
at 6 months of age. Human astrocyte specific antibodies (red) and
non-species-specific total glial fibrillary acidic protein (GFAP; green) staining
was done in different brain regions. Original images were collected by a Leica
DM6

system

(Leica

Microsystems,

Wetzlar,

Germany)

with

1000×

magnification. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI;
blue). Bar = 20 µm. (B) Oligodendrocyte specific nuclear staining (Olig2;
green) and total human-specific nuclear (hN) staining was done in different
brain regions. The original magnification was 400×. Bar = 50 µm. Results from
one of two performed experiment are shown. (C) Quantitative data showing
the number of human astrocytes from one of four experiments with ten
animals. The average percentage of human cells was assessed on 2–4
representative sagittal sections from each mouse for a selected field of view of
the same brain region. Each symbol represents an individual mouse and lines
indicate mean and standard error of the mean (SEM). (D) Proportion of human
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oligodendrocytes among human glial cells in different brain regions. Dotted
line on (B) demarcates the corpus callosum (CC) from the frontal cortex (FC).
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Figure 3.3. Immune repopulation of peripheral blood and the mouse brain. (A)
Fluorescence-activated cell sorting (FACS) analysis of peripheral blood.
Representative plots of human cluster of differentiation 45 (CD45)+ cells and
human CD3, CD19, and CD14 cells gated from the CD45 lymphocyte
population. CD8 and CD4 cells were gated from CD45+ and CD3+ cell
populations. (B) Percentage of human cells in peripheral blood of all dual
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reconstituted mice used in the studies. Each symbol represents an individual
mouse. (C) Representative images of the distribution of human immune cells
in the brain. Paraffin embedded 5-µm thick sections were stained for
human-specific

markers:

human

leukocyte

antigen-antigen

D

related

(HLA-DR), CD163, CD4, and CD8. Representative images from different brain
regions are shown. Images were captured by a Nuance multiplex system (CRi,
Wobum, MA) with an original magnification of 200×. Insets represent cells with
a magnification of 1000×. Bars = 100 µm and 20 µm (inset). (D and E)
Quantification of human cells positive for HLA-DR, CD163, CD8, and CD4 in
selected regions. Numbers represent frequencies of positive cells per section;
7 mice were analyzed. Human-specific antibodies did not cross-react with
non-humanized tissues (not shown).
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Figure 3.4. Biological processes altered by humanization. Gene Ontology
(GO) enrichment analysis for gene sets identified as differentially expressed
according to mouse database and predicted biologic processes in mouse brain
associated with humanization of mouse immune system and brain glial
compartment.
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Donor #,

Viral copies/mL
+

Animal
cells

CD45 cells
Gender

in PB or
a

ID

In PB , %
IHC P24+ in spleenb

842c

F

49.0

1.89 x104

844

F

64.3

2.05 x 106

845

F

57.4

P24+

848

M

62.4

P24-

843

F

52.2

846

F

81.1

847

F

85.1

849

M

72.2

850

M

60.0

853

F

51.6

1.50 x 105

854

F

48.1

6.14 x 105

855

F

67.4

P24+

2

857

M

58.4

P24+

CD34+NPC

858

M

49.6

3.30 x 105

851

F

55.3

852

F

34.8

856

M

39.4

1
CD34+NPC

75

859

M

59.5

860

M

65.2

861

F

87.2

P24+

862

F

88.3

6.30 x 104

864

F

93.4

P24+

867

M

86.8

P24+

868

M

75.6

3.05 x 104

869

M

48.7

1.15 x 105

865

F

82.3

866

F

70.8

870

M

67.9

871

M

68.6

881

F

43.0

P24+

883

F

45.1

P24+

884

F

54.8

P24+

885

F

57.3

3.90 x 106

886

F

67.8

9.19 x 105

887

F

67.1

P24+

888

M

34.1

P24+

893

M

47.2

P24+

882

F

52.4

3
CD34+NPC

4
CD34+NPC

76

5

889

M

58.1

890

M

20.2

891

M

64.2

892

M

38.6

894

M

46.3

895

M

51.3

896

M

78.2

2464

F

68.0

2465

F

69.8

2466

F

65.6

d

CD34

Table 3.1. Animal information.
a.

PB, peripheral blood

b.

IHC P24, positive staining of human cells for HIV-1 p24 protein in spleen

sections
c.

Red font color indicates mice infected with HIV-1.

d.

Mice only reconstituted with human CD34+ cells
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A. Brain region - Hippocampus
Unmapp

Aligned

Aligned
Total
Mouse

Aligne
Aligned,

ed

to to

to mouse
reads

d
%

mouse

human

db

%
db

db

NSG 1

51014897

48087583

94.26

NSG 2

41652143

39018734

93.68

NSG 3

46959446

44511795

94.79

865

46956130

43421923

92.47

3634305

1372101

37.75

866

40829365

37037892

90.71

3922047

1960111

49.98

870

50793540

47210898

92.95

3669575

1210544

32.99

862-HIV

43135303

39972433

92.67

3229431

838062

25.95

868-HIV

35981612

31455849

87.42

4596462

984201

21.41

869-HIV

31713932

28145288

88.75

3632558

855669

23.56
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B. Brain region – Corpus Callosum
Aligned
Aligned
Total
Mouse

Unmapped
Aligned,

to mouse
reads

to

Aligned,

human

%

mouse

%
db

to

db
db

NSG 1

45441189 43553086

95.84

NSG 2

30165210 26937369

89.30

NSG 3

41990884 39445457

93.94

865

45264610 42909810

94.80

2398270

622385

25.95

866

38643985 36193215

93.66

2499633

722320

28.90

870

46034814 43766894

95.07

2294914

398541

17.37

862-HIV 50495226 47149758

93.37

3415952

962671

28.18

868-HIV 41272990 38694696

93.75

2626259

683299

26.02

869-HIV 50576101 47508501

93.93

3131638

840446

26.84

Table 3.2. RNA sequencing summarya
a

- RNA sequences generated from high-throughput sequencing were aligned

to the mouse genome (mm10). Resultant unaligned sequences were then
aligned to the human genome (hg19).
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3.5 Materials and Methods
3.5.1 Animals, cell transplantation
Newborn NOD/SCID/IL2Rγc−/− (NSG, stock No: 005557, The Jackson
Laboratory, Bar Harbor, ME, USA) mice were bred at the University of
Nebraska Medical Center (UNMC). P0-1 litters were irradiated with 1 Gy (RS
2000 X-ray Irradiator, Rad Source Technologies, Inc., Suwanee, GA, USA).
Pups were intrahepatically injected with 5 × 105 CD34+ HSCs. These mice
were simultaneously transplanted with 1 × 105 NPCs into the right lateral
ventricle. Blood samples collected from the facial vein were evaluated by flow
cytometry starting 8 weeks post-engraftment to monitor expansion of human
leukocytes. Mice characteristics are listed in Table 3.1. Animal procedures
strictly followed the Institutional Animal Care and Use Committee-approved
protocols at UNMC.

3.5.2 Neural progenitors isolation and culture
Human neural progenitors were isolated from human fetal brains provided by
the University of Washington Medical Center Laboratory of Developmental
Biology (R24HD000836-51). The protocol was approved by the UNMC
Scientific Research Oversight Committee (SROC) and Institutional Review
Boards at the University of Washington Medical Center and UNMC. Cell
isolation and culture were done as previously described [196]. Briefly, single
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cell suspensions were cultivated in NS-A medium (STEMCELL, Mountain
View, Canada) containing N2 supplement (1:100; Fisher Scientific, Waltham,
MA, USA), neural survival factor-1 (NSF1; 1:50; Lonza, Walkersville, MD,
USA), LIF (10 ng/ml; Sigma-Aldrich, St. Louis, MO, USA), epidermal growth
factor (EGF; 20 ng/ml; Fisher, MA, USA), and basic fibroblast growth factor
(bFGF; 20 ng/ml; STEMCELL, Mountain View, Canada) for 14 days before
passage. Four hours before injection, the neurospheres were dissociated into
single cell suspension with 0.25% Trypsin (Gibco, Grand Island, NY, USA).
The single cell suspensions were plated on polystyrene-coated coverslips and
cultured for 48 hours in vitro. Immunofluorescent cytology was applied to
investigate the differential potential of NPC.

3.5.3 Human hematopoietic stem cells (HSCs) isolation
Matched to the brain sample, fetal liver tissue was processed with 0.5 mg/ml
DNase, collagenase, and hyaluronidase (all from Sigma-Aldrich, St. Louis,
MO, USA) using gentleMACS™ Dissociator (Miltenyi Biotec, Auburn, CA,
USA). Cell suspensions were passed through a 40-µm cell strainer and then
centrifuged through leukocyte separation medium (MP Biomedicals, Santa
Ana, CA, USA) at 100 g for 30 min, with acceleration set to 9, and deceleration
set to 1. The intermediate layer of cells was collected for positive isolation of
CD34+ cells using a magnetic isolation kit (Miltenyi Biotec, Auburn, CA, USA).
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CD34+ cells were stored in liquid nitrogen using a freezing medium with 50%
fetal bovine serum (FBS), 40% Roswell Park Memorial Institute (RPMI)-1640
medium (Hyclone, Logan, UT, USA), and 10% dimethyl sulfoxide (DMSO;
Sigma-Aldrich, St. Louis, MO, USA).

3.5.4 Flow cytometry
Blood samples were collected from a facial vein in ethylenediaminetetraacetic
acid (EDTA)-containing tubes (BD Microtainer, Franklin Lakes, NJ, USA) and
centrifuged at 300 g for 5 min. Plasma was stored for HIV viral load
measurements. Blood cells were reconstituted in a buffer of 2% FBS in
phosphate buffered saline and incubated with antibodies against human cell
markers, including CD45+ fluorescein isothiocyanate (FITC), CD3+ Alexa700,
CD19+ R-phycoerythrin (PE) cyanine 7 (Cy7), CD4+ allophycocyanin (APC),
CD8+ Brilliant VioletTM 450 (BV450), and CD14+ PE for 30 min at 4°C.
Information on all of the antibodies are listed in S3 Table. Samples were
analyzed using a BD LSR2 flow cytometer [182]. Gates were assigned
according to the appropriate control population.

3.5.6 Immunohistochemistry
Brain tissue was cut sagittally for both the left and right hemispheres, fixed with
4% paraformaldehyde for 24 hours at 4°C, and then embedded in paraffin.
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Paraffin-embedded 5-m thick tissue sections were processed with Declere
Solution (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s
instructions. Tissue was blocked with 10% normal goat serum in Tris-buffered
saline and 0.05% Tween 20 (TBST) for 45 min and then incubated with mouse
(ms) anti-human GFAP (1:200; Abcam, Cambridge, MA, USA), ms anti-human
nuclear antigen (1:200; Millipore, Billerica, MA, USA), ms anti-human
cytoplasmic marker (1:1000; STEMCELL, Mountain View, Canada), ms
anti-HIV-1 p24 (1:10; Dako, Carpinteria, CA, USA), ms anti-HLA-DR (1:500;
Dako, Carpinteria, CA, USA), ms anti-CD163 (1:50; Thermo Scientific, Denver,
CO, USA), rabbit (rb) anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and rb
anti-human CD4 (1:500; Abcam, Cambridge, MA, USA). Secondary antibodies
were goat anti-ms and goat anti-rb immunoglobulin G (IgG) horseradish
peroxidase (HRP; Dako, Carpinteria, CA, USA). Bright field images were
captured and photographed using 20× and 100× objectives on a Nuance
Multispectral Tissue Imaging system (CRi, Wobum, MA). Immunostained
sections were scanned using a high-resolution scanner (Ventana Medical
Systems, Inc., Oro Valley, AZ, USA). DEFINIENS Tissue Studio® software
(Definiens AG, Munich, Germany) was used to analyze the brain sections
stained for human glial and immune cells. None of human-specific antibodies
had cross-reactivity and stained control non-humanized mouse brain sections.
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3.5.7 Immunofluorescence
For immunofluorescent staining of paraffin-embedded tissue, sections were
processed and blocked as described above. Ms anti-human GFAP (1:200;
Abcam, Cambridge, MA, USA), ms anti-human nuclei (1:200; Millipore,
Billerica, MA, USA), rb anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and
rb anti-Oligo2 (1:500; PhosphoSolutions, Aurora, CO, USA) were applied. For
immunofluorescent characterization of cultivated NPC, ms anti-human GFAP
(1:200; Abcam, Cambridge, MA, USA), ms anti-MAP2 (1:200; Santa Cruz,
Santa Cruz, CA, USA), ms anti-glutamic acid decarboxylase 67 (GAD67;
1:500; Millipore, Billerica, MA, USA), rb anti-nestin (1:200; Millpore, Billerica,
MA, USA), and rb anti-Tuj-1 (1:500; Biolegend, San Diego, CA, USA) were
applied. Secondary antibodies were goat anti-ms IgG Alexa 488 (1:00;
Invitrogen, Grand Island, NY, USA), goat anti-ms IgG Alexa 594 (1:00;
Invitrogen, Grand Island, NY, USA), goat anti-rb IgG Alexa 488 (1:100;
Invitrogen, Grand Island, NY, USA), and goat anti-ms IgG Alexa 594 (1:00;
Invitrogen, Grand Island, NY, USA). A Leica DM6 system (Leica
Microsystems, Wetzlar, Germany) and a Zeiss LSM510 confocal system (Carl
Zeiss

Microscopy

GmbH,

Jena,

Germany)

were

also

used

for

immunofluorescent imaging. The intensity of illumination and the position of
the sub-region on the microscope were consistent across all images.
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3.5.8 RNA isolation and next generation sequencing
Left hemispheres of the reconstituted mouse brains were preserved in
RNALater (Invitrogen, Grand Island, NY, USA). The corpus callosum and
hippocampus from three HIV-infected dual reconstituted mice, three control
dual reconstituted mice, and three non-manipulated NSG mice were
micro-dissected and transferred to 700 µl of QIAzol solution (QIAGEN,
Valencia, CA, USA) for RNA isolation using an RNeasy Mini kit (QIAGEN,
Valencia, CA, USA). After RNA integrity was analyzed, samples were deep
sequenced using 100 bp/read, up to 40 million reads/sample using an Illumina
HiSeq 2500 Sequence Analyzer (Illumina, Inc., San Diego, CA, USA). For both
the hippocampus and corpus callosum, we compared the control samples
(NSG1–3) to the humanized mouse samples (865, 866, 870), and the
humanized mouse samples to the humanized mouse samples with HIV (862,
868, 869). The reads were mapped to the mm10 mouse genome and the
mouse transcriptome. A third comparison was also made whereby humanized
mouse samples (865, 866, 870) were compared with humanized mouse
samples with HIV (862, 868, 869), but mapped to the hg19 human database.
For both tissues, we collected the unmapped reads, which did not map to the
mouse genome, and remapped them to the human genome. This was done in
order to see what human genes were expressed in these tissues. The cuffdiff
algorithm was used to identify differentially expressed genes; all significant
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genes were reported with an FDR adjusted p-value of 5% for all cuffdiff
comparisons. Cuffdiff was specifically used because it normalizes the
expression values and protects against overdispersion so that the values fit
into a normalized bell curve [200]. The number of total reads and alignment
results are shown in Table 3.2.

3.5.9 Statistical analysis
Values

from

all

quantifyed

cell

types

(astrocytes,

oligodendrocytes,

macrophages and lymphocytes) and groups were averaged; multiple t-tests
using the Holm-Sidak method for multiple comparisons correction was applied
to examine significant differences between groups. Two-way analysis of
variance (ANOVA) using Sidak’s multiple comparisons correction was used to
examine significant differences between groups. For RNA sequencing data,
the tophat/cuffdiff pipeline was run on the reads for each sample in order to
identify differentially expressed genes [200].
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CHAPTER - 4
HIV-1 Infection and Glial Innate Immune Response in
the Combinatorial Humanized Mouse Model
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4.1 Abstract
A mouse model with dual humanized brain and immune system was created to
bridge the gap in deciphering complex neuroimmune communication networks
seen during progressive HIV-1 infection. Immune analyses of these
HIV-1-infected mice showed meningeal and perivascular infiltration by human
leukocytes and surveillance by activated immune cells in brain tissue. The
molecular mechanisms underlying species-specific virus-immune system-brain
tissue interactions were identified by deep RNA sequencing. In the corpus
callosum

and

hippocampus

of

HIV-1

infected

animals

overlapping

human-specific transcriptional alterations were seen for interferon (IFN) type 1
and 2 signaling pathways (STAT1, 2, IRF9, MX1, ISG15, IFI6, CMPK2) and a
range of host antiviral responses. Human viral defense mechanisms including
linked cytokine signaling patterns closely resembled what was observed by
others in human HIV-1 encephalitic brains. Differentially expressed mouse
genes in the hippocampus reflected tissue remodeling while down-regulated
human genes were linked to altered cell growth, glial cytoskeleton
reorganization, oligodendrocyte differentiation and myelin ensheathment
(MBP, MOBP, PLP1, MAG and ZNF488). These results were confirmed by
real-time PCR tests. We conclude these mice can provide human
disease-specific viral-glial communication cues and may facilitate discovery of
new therapeutics targets for HIV-1 nervous system infection.
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4.2 Introduction
Although the HIV-infected humanized mouse models have been characterized
extensively for their ability to recapitulate the human immune response against
HIV, and been applied widely to test the efficacy of therapeutic approaches,
they are insufficient to assess HIV-associated neuropathology and related
neurocognitive dysfunctions. As introduced in the previous chapter, a new
mouse models with combined human immune system and glial cells (primarily
astrocytes and oligodendrocytes) reconstitution were created to further dissect
neuroimmune interactions during progressive HIV-1 infection.
We investigated the pathological and molecular changes in this dual
reconstituted mouse model after being infected with macrophage-tropic
HIV-1ADA. The Immune analyses of these HIV-1-infected mice showed
meningeal and perivascular infiltration by activated human immune cells in
brain tissues. Deep RNA sequencing revealed transcriptional signatures that
were linked to activation of IFN type 1 and 2 signaling pathways (STAT1, 2,
IRF9, MX1, ISG15, IFI6, CMPK2) and a range of host antiviral responses in
HIV-1 infected animals. While down-regulated human genes were linked to
altered cell growth, glial cytoskeleton reorganization, oligodendrocyte
differentiation and myelin ensheathment (MBP, MOBP, PLP1, MAG and
ZNF488). The results surprisingly overlapped with the disease profile observed
by others in human HIV-1 encephalitic brains. This new model provided a
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promising future for study of human-specific viral-glial interactions and
discovery of new therapeutics targets for HIV-1 nervous system infection.

4.3 Results
4.3.1 HIV-1 infection of dual humanized mice
As described in Chapter 3, the dual humanized mice were created by
transplanting newborn NOD/SCID/IL2Rγc−/− mice both with human NPCs and
HSCs. At 24 weeks of age, mice were divided into two groups. Each showed
similar human immune reconstitution. One group was infected with HIV-1ADA
intraperitoneally with 104 infectious particles in a volume of 100 µl/mouse. At 6
weeks after infection, HIV-1 p24+ stained cells were present in the spleens (Fig
4.1 A), with a median of 1.58 × 105 viral RNA copies/ml in blood (Fig 4.1 B).
Peripheral immune cells infected by HIV were in the meninges but rarely in the
perivascular space (Fig 4.1 C). Flow cytometric analyses performed at 6
weeks after infection showed a drop from 80% to 60% of CD4+ T cells among
the CD3+ population (P < 0.05). An increase in the CD8+ T lymphocytes was
seen in a proportion to CD4+ T cell depletion (Fig 4.1 D and E).
An unbiased digital image analysis workstation (DEFINIENS Tissue
Studio®, Cambridge, MA, USA) was used to analyze human glial cell
repopulation and immune cell brain infiltration. In comparison to non-infected
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controls, HIV-1-infected mice had a lower number of human astrocytes/sagittal
section. However, the total number of nucleated cells/sagittal section remained
consistent across the animal groups (Fig 4.1 F). A statistically significant
two-fold increase in the number of brain infiltrating peripheral immune cells
following HIV-1 infection was observed when compared to uninfected dual
reconstituted mice (Fig 4.1 G). However, the presence of human glial cells did
not increase the numbers of human leukocytes within the meninges and
parenchyma compared to age-matched peripherally reconstituted humanized
mice.

4.3.2 Transcriptional changes in the humanized mouse brain
To assess the pathobiological outcomes of viral infection following peripheral
immune and brain humanization, we applied deep sequencing to assess
transcriptional profiles seen as a consequence of glia-immune crosstalk. We
selected three infected animals with similar patterns of human immune cell
repopulation, astrocyte distribution and peripheral viral loads for study. Three
equivalent aged NSG uninfected mice served as controls (Fig 4.2 A). Hip and
CC repopulated by human glial cells were dissected for sequencing (Fig 4.2
C). All sequenced reads (~100 bp length) were aligned to the mouse database
(University

of

California

Santa

Cruz

Genome

Browser

database,

GRCm38/mm10). The experiment was designed to search for differentially
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expressed mouse transcripts as a result of human cell engraftment and
HIV-1-infection. Subsequently, the reads unmapped to the mouse genome
were re-aligned to the human genome (GRCh38/hg19) to find human specific
transcriptional changes. The overall mapped mm10 reads average ratio was
92% for all 9 Hip samples and 94% for all 9 CC samples (Table 3.2). For the
HIV-1-infected and uninfected humanized mice, the mouse database was run
against its human counterpart. The average ratio for mapped reads was 32%
and 26% for the Hip and CC, respectively. Analyses using the mouse
database identified 365 differentially expressed transcripts in the Hip and 93 in
the CC as a result of the engraftment of human glial cells. When compared to
humanized mouse transcripts, few mouse transcripts were differentially
expressed as a result of HIV-1 infection. When the reads unmapped to the
mouse genome were realigned to the human reference genome, 115 and 58
human transcripts were found differentially expressed in the Hip and CC,
respectively, following infection (Fig 4.2 D). The low numbers of HIV-1gag
RNA was detected in selected brain regions (Fig 4.2 B). The alignment to
HIV-1ADA genome detects gag (1), pol (3), tat (2) and vif (1) reads of transcripts
in CC of two animals. In Hip samples of infected animals HIV-1 mRNA
transcripts were not found.
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4.3.3 Region-specific alterations of mouse transcriptom by HIV-1
infection in combinatorial humanized mice
We used GeneCards® integrative database to obtain categorized results for
differentially expressed mouse genes. This was done to identify Gene
Ontology (GO) gene sets related to mouse brain humanization. The obtained
information about the biological roles of the genes of interest we summarized
in Fig 3.4 Glial humanization of mouse brain with a human peripheral immune
system induced transcriptional changes associated with multiple biological
processes. The complete set of differentially expressed genes for mouse
transcriptome comparisons between NSG and HIV-1 infected humanized mice
is listed in the 4.1 Table.

4.3.4

Non-overlapping

alterations

in

the

human

and

mouse

transcriptomes following viral infection
In comparison to uninfected mice, brains with virus-infected human showed
signature expression patterns of 45 and 56 genes in the CC and Hip,
respectively (Fig 4.2 E). In the CC, the up-regulated genes were strongly
associated with type 1 and 2 IFN responses and specific signaling pathways.
These were linked to host viral defense responses (MX1, IFIT families,
PLSCR1, EIF2AK2, IFI16, ADAR, OAS3, MX1, BST2, RSAD2), RNA
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catabolism (CMPK2, PNPT1), ISG15-protein conjugation, regulation of type 1
IFN production (HERC6, ISG15, DXT3L, DDX58, PPAR9, PPM1K) and
cytokine-mediated signaling (Table 4.2).
In addition, up-regulated genes associated with norepinephrine metabolic
processes (EPAS1, LY6E) and those related to neural differentiation
(PARP10, GARS, AGRN, SOX10) were found. In the CC and Hip, the
identified down-regulated genes were linked to myelination and axon
ensheathment (MBP, MOBP, MAG, PLP1, CLDN11), neural progenitor
differentiation (STMN2, ZNF488, IGFBP5, BIN1, APLP1), glial structural
integrity, lipid metabolism, ion transportation and cell cycle regulation (Table
4.2 and 4.3). Alignment to the mouse database reads in the uninfected and
HIV-1-infected humanized mice showed non-overlapping up-regulated gene
patterns. These were related to blood vessel development and extracellular
matrix re-organization (ALDH1A2, TCF7L2, COL1A2, COL5A1, FMOD, BMP7)
as well as neurotransmitters, sugars, organic acids, anion transmembrane
transport (SLC6A13, SLC6A20, SLC22A6, SLC13A4), and cellular responses
to hormone stimulus (IGFBP2, RAMP3). Few down-regulated genes were
observed (ST18, CMSS1). The obtained by GeneCards® integrative data base
information about the biological roles of the genes of interest we summarized
in Fig 4.4. The identical biologic processes were found in CC and Hip that
characterize the well-known responses of human glial cells and immune cells
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to HIV-1 infection. The mouse biological responses to HIV-1 infection in this
new chimeric system were not virus or immune responses related.

4.3.5

Human

astrocytes

produce

type

1

IFN

during

infected

macrophage-astrocyte co-cultivation
The up-regulated expression of type 1 IFN and the related response in the
chimeric murine brains following HIV-1 infection led to investigation of the type
1 IFN cell source. Though almost all nucleated cells can produce type 1 IFN,
plasmacytoid dendritic cells are the most potent IFN producers [201].
However, prior studies have demonstrated that astrocytes abortively infected
by neurotropic viruses are also a potent source of IFN beta (IFN-β) in mice
[186]. To identify the source of type 1 IFN in response to HIV-1 infection, we
used

transwell

systems

to

co-culture

human

fetal

astrocytes

and

HIV-1-infected monocyte-derived macrophages (MDM). After 3 days of
co-culture with HIV-1-infected MDM and astrocytes, astrocytes were found to
produce IFN-β. The levels of IFN-β reached a peak at 5 days. Three
independent donors were used; a representative experiment is shown in Fig
4.5. The concentration of IFN-β produced by HIV-infected MDM alone
remained at relatively low levels (approximately 15 pg/ml, detection limit). The
concentration of IFN-β in control astrocytes and MDM were below detectable
throughout the experimental observation period.
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4.3.6 RT-PCR confirmation of affected human genes in humanized
mouse brain tissues
To confirm the altered expression and the species specificity of the IFN
signaling pathway related transcripts, we applied real-time PCR assays to
reexamine the selected genes found affected in RNA-sequencing using human
and mouse specific primers and probes. As critical elements of the upstream
of type 1 IFN response pathway, STAT1, STAT2 and IRF9 were found 3.72,
1.69, and 3.64 times (P<0.05) up-regulated in the CC of HIV-1-infected dual
reconstituted mice, respectively, compared to that of control dual reconstituted
mice. Up-regulation of these three genes was found in the Hip of HIV-infected
humanized mice as well (Fig 4.6 A - C). The down-stream IFN inducible
genes such as MX1, ISG15, IFI6 and CMPK2 were also found significantly
up-regulated in both CC (12.09, 11.69, 9.41 and 13.69 times, respectively,
P<0.05) and Hip (19.90, 15.90, 9.17 and 21.25 times, respectively, P<0.05) of
HIV-1 infected humanized mice compared to the control animals (Fig 4.6 D G). Among the myelination and glial integrity associated genes, the expression
of MBP was reduced 2.94 and 2.5 times (P<0.05) in the Hip and CC of HIV-1
infected mice, respectively (Fig 4.6 H). The expression of ZNF488 was only
found significantly down-regulated in the CC of HIV-1 infected group, but not in
the Hip (Fig 4.6 I). The assays using mouse-specific primers and probes failed
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to demonstrate any gene expression difference between HIV-1 and control
groups.

4.4 Discussion
We created a unique mouse model that contains both a human immune
system and human glial cells in the brain. The animals were used to
investigate the consequences of HIV-1 infection on brain pathobiological
processes. Sustained infiltration of lymphocytes and macrophages were
readily seen and altered nervous system microenvironment [177]. These
results paralleled a previously demonstrated accelerated entry of human
CD163+ macrophages and T lymphocytes into the brains of infected
humanized mice in the absence of glial reconstitution [182]. Specifically,
increased numbers of HLA-DR cells infiltrated into dual reconstituted mouse
brains. This was seen in comparison to mice reconstituted only with a human
immune system. Moreover, an increased number of human leukocytes
infiltrated glial reconstituted brains after systemic infection.
As the most abundant cell type in the brain, astrocytes react to injury or
viral infection through cellular activation [202]. Inefficient viral entry due to lack
of CD4-receptors and limited expression of CXCR4 and CCR5 has been
suggested as a major obstacle to astrocyte infection [203]. Thus, while most
researchers would agree that highly restricted infection of astrocytes can occur
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[204] whether it can affect brain homeostatic and antiviral responses was not
previously recognized in depth. In the present study we found low levels of
HIV-1gag mRNA expression in infected mice brains and failed to find human
astrocytes that were HIV-1p24 protein positive by immunohistology. Very
limited number of viral mRNA transcripts were detected in CC of two animals,
when sequencing reads were aligned to HIV-1ADA genome, while in Hip
samples of infected animals HIV-1 mRNA transcripts were not found.
Nonetheless, significant innate human antiretroviral responses were observed
in these chimeric mice.
For the first time, combinatorial blood-brain humanized mice were made,
infected with HIV-1 then analyzed by RNA-sequencing for species-specific
reaction. We followed a similar strategy to that of chimeric tissue
transcriptomic analysis described for humanized mice carrying syngeneic
tumor and immune tissues. In this case humanizing mouse bone marrow
enables microenvironment reconstitution in a patient-derived xenograft [205].
Comparison of transcriptional changes in the immune responses of humans
and mice associated with the non-species-specific bacterial pathogen S.
aureus, has shown to be highly correlative [206]. Nevertheless, transcriptional
changes induced in the brain of chimeric animals by HIV-1 should be
human-specific. Indeed, our findings in the transcriptome of HIV-1-infected
dual reconstituted mice corroborated this idea. More than 30 human genes
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significantly up-regulated in the CC and Hip were found to be closely related to
innate and adaptive immunity, HIV host restriction factors, and IFN stimulated
factors (Table 4.2 and 4.3). Noticeably, STAT1/STAT2 and IRF9 can form a
transcriptional complex upon activation of type 1 IFN receptors [207]; this
complex can subsequently translocate to the nucleus and induce the
expression of a broad spectrum of IFN-stimulated genes [208]. Among these
IFN stimulated factors, MX1, OAS3, RSAD2 (viperin), and all the IFI and IFIT
family are involved in combating viruses at nearly every stage of the viral life
cycle. For instance, IFN-inducible transmembrane proteins (IFITMs) and
tripartite motif proteins (TRIMs) can act during viral entry and uncoating [209].
Myxoma resistance proteins (MXs) block nucleocapsid transport [210].
Inhibition of RNA reverse transcription, protein translation, and stability are
mediated by SAM-domain- and HD-domain-containing protein 1 (SAMHD1),
adenosine deaminase, RNA-specific 1 (ADAR1), 2′-5′ oligoadenylate
synthases (OASs), IFN-stimulated gene 20 kDa protein (ISG20), and ISG15
[120, 211-213]; viperin and tetherin help to prevent viral assembly and release,
respectively [214-216]. Some of the effectors, such as MX proteins, appear to
operate in both the nucleus and the cytosol [210]. Therefore, human glial cells
in the mouse brain are able to restrict, in measure, productive viral infection
through a robust type 1 IFN response. The up-regulation of the human specific
IFN signaling related genes were confirmed by real-time PCR assays using
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human specific primers and probes (Fig.4.6). We also confirmed by RT-PCR
upregulation of rare mRNA transcript identified by RNA sequencing for
CMPK2, which could belong to infiltrating human macrophages and serve as a
viral restriction factor [217]. However, no change in expression of the host
restriction factors were reflected in the mouse transcriptional profile as result of
HIV-1 infection, which is consistent with the confirmatory real-time PCR
assays. This observation reflects that HIV-1 can neither efficiently enter mouse
cells due to the absence of specific receptors, nor trigger a pattern recognition
response by murine cellular defense machinery.
This vigorous type 1 IFN further leads to the question of what cell source
produces type 1 IFN in these dual reconstituted mouse brains. Due to the
increased infiltration of macrophages into the brain during systemic HIV-1
infection in these mice, and astrocyte production of IFN-β[186], we were able
to confirm the source of IFN-β; we posit that astrocyte secretion of IFN-β
occurs through its interactions with infected macrophages. The transwell
co-culture of HIV-1ADA-infected MDM and astrocytes revealed the temporally
dependent dynamics of IFN-β production.
Through the use of unbiased image analysis we found a limited yet
significant decrease in the number of human astrocytes in the brains of
chimeric mice infected with HIV-1. The cellular machinery that astrocytes used
to protect themselves from productive viral infection could create an
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inflammatory cascade. This could then lead to restricted astrocyte infection
and programmed cell death [218]. A similar scenario is known to occur in
quiescent CD4 T cells, which undergo an abortive infection with accumulation
of incomplete HIV reverse transcripts [219]. In support of this theory, our data
showed significant up-regulation of genes serving as cytoplasmic sensors for
nucleic acids, such as DDX58 and IFI6. The downstream signaling and effects
of these single- and double-strand RNA sensors in astrocytes are therefore
worthy of further investigation.
Furthermore, the deep sequencing also captured several significantly
up-regulated transcripts in the chimeric brains, such as C19orf66, which has
potential as an IFN-stimulated inhibitor of the dengue viral infection [220].
Moreover,

the

lectin,

galatoside-binding,

soluble

3

binding

protein

(LGALS3BP) has been found to be elevated in the serum of HIV infected
patients and is involved in interference with the incorporation of HIV-1
envelope glycoprotein molecules into virions [221]. In the Hip, in addition to the
up-regulated genes introduced previously, class I HLA genes were also found
to be up-regulated, which is yet another downstream effect of the type 1 IFN
response.
The identified down-regulated genes are mostly critical for oligodendrocyte
differentiation and myelination, cell growth, and glial structural constituents.
Among them, zinc finger protein 488 (ZNF488) is a critical transcriptional factor

101

that interacts and cooperates with Olig2 to promote oligodendrocyte
differentiation [222]. PLP1, MAG, MOBP, and MBP are encoding structure
proteins of the myelin sheath. CLDN11 encodes a crucial component of the
tight junctions between the myelin sheath [223]. In claudin11 knockout mice,
action potential propagation was compromised due to the dissipation of
electrical current through myelin [224]. Together, all of these molecular
changes suggest early alterations in the structure and function of white matter
during HIV infection. This may potentially lead to a compromise in the integrity
of the glial system and consequent neural dysfunction. For example, a
previous study showed decreased expression of myelin proteins, like MOG
and MAG, from 12–17 weeks post-infection in humanized mice only
reconstituted with a human immune system [183]. Additionally, the
transcriptional changes in HIV-1 transgenic rat also demonstrated a decreased
expression of genes encoding myelin proteins in regions like frontal cortex and
striatum [225]. Our dual reconstituted mice were only observed for 6 weeks
after infection, and human-specific transcripts were already down-regulated.
Therefore, a longer period of infection may be necessary for observing
transcriptional and morphological changes in mouse oligodendrocytes and
myelin structure. This new model is a step forward as compared to other
humanized mice that are widely utilized for HIV-1 research notwithstanding the
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additional need for human neurons to fully assess HIV-1-associated
neuropathology.
In summary, the dual reconstituted chimeric mouse model allowed us to
investigate how glial-immunocyte crosstalk is affected by HIV-1 infection.
Using sequencing we found that the transcriptional profiles from the chimeric
brains overlap, in large measure, with the disease profile found in human
HIV-1 encephalitic brains [176, 226]. These findings underscore the protective
role astrocytes have in defending the brain from HIV-1 infection. This model
also provides a platform to further investigate the HIV nervous system
reservoirs and develop novel disease combating therapies.

103

104

Figure 4.1. Effects of HIV-1 infection on dual blood and brain humanized mice.
(A) Immunohistology of spleen sections shows clusters of human leukocyte
antigen-antigen D related (HLA-DR) positive cells and the presence of
HIV-1-infected cells stained for HIV-1 p24. Images were captured by a Nuance
multiplex system (CRi, Wobum, MA) with an original magnifications of 200×.
Bar = 100 µm. (B) Peripheral viral load determined by quantitative real-time
polymerase chain reaction (PCR) using a COBAS Amplicor System (Roche
Molecular Diagnostics, Pleasanton, CA, USA). Each symbol represents an
individual infected mouse from all experiments. (C) Immunohistology of brain
sections showing the presence of activated HLA-DR+ cells and HIV-1 p24+
infected cells on adjacent serial sections. Representative images from the
meningeal space containing vascular vessels are shown. Images were
captured by a Nuance multiplex system with an original magnification of 200×.
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Insets represent cells with a magnification of 1000×. Bars = 100 µm and 20 µm
(inset). (D) Examples of representative plots showing cluster of differentiation
4 (CD4)+ cell decline in peripheral blood of HIV-1-infected mice, with a relative
increase in the CD8+ cell compartment. (E) Quantification of human CD4 and
CD8 T cells in the peripheral blood of infected (n = 6) and control (n = 6) mice.
Multiple t-tests using the Holm-Sidak method for multiple comparisons
correction was applied to examine significant differences between groups.
Bars = means ± standard error of the mean (SEM); *P < 0.05. (F)
Quantification of human glial fibrillary acidic protein (GFAP)+ and all nucleated
cells on representative sagittal brain sections of HIV-1-infected (n = 18) and
control (n = 19) mice. Unpaired t-tests were used to examine significant
differences between groups. Bars = means ± SEM; *P < 0.05, ns = no
significance. (G) Quantification of infiltrating HLA-DR+ and CD163+ cells in the
brain regions of HIV-1-infected dual reconstituted mice (HIV-Dual hu, n = 5),
control dual reconstituted mice (Control-Dual hu, n = 6), and mice only
reconstituted with human peripheral immune cells (Control-Peri hu, n = 3).
Two-way analysis of variance (ANOVA) using Sidak’s multiple comparisons
correction was used to examine significant differences between groups. Bars =
means ± SEM; *P < 0.05, ****P < 0.0001.
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Figure 4.2. HIV-1 infection induced transcriptional changes in the brains of
humanized mice. (A) Characteristics of peripheral reconstitution and the levels
of HIV-1 infection of mice selected for ribonucleic acid (RNA)-sequence
analysis (n = 3 per group). Percentage of lymphocyte sized cells, human
cluster of differentiation 45 (CD45), CD3, CD4, and CD8 cells, as well as HIV-1
viral load in the peripheral blood of HIV-1-infected dual reconstituted mice
(HIV+, red symbols), control dual reconstituted mice (control, blue symbols),
and

non-manipulated

non-obese

diabetic

(NOD)/severe

combined

immunodeficient (SCID)/interleukin 2 receptor γc (IL2Rγc)−/− control mice
(NSG, grey symbols). (B) Viral RNA levels were determined by semi-nested
real time polymerase chain reaction (PCR) in the HIV+ group (n = 3, red
symbol) and the control group (n = 3, blue symbol). Viral nucleic copies were
normalized to the total RNA quantity isolated from brain regions. (C)
Representative image of human glial cell reconstitution and scheme of corpus
callosum (CC) and hippocampus (Hip) microdissection. (D) Identification of
differentially expressed transcripts in CC (upper pie chart) and Hip (lower pie
chart). Sequenced reads were mapped to the mouse database (mm10) and
comparisons were conducted: 1) between non-manipulated NSG mice and
dual reconstituted NSG mice (NSG vs. huNSG, blue color); 2) between dual
reconstituted NSG mice and HIV-1-infected dual reconstituted NSG mice
(huNSG vs. HIV-huNSG, red color). Reads unmapped to the mm10 database
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were realigned to the human database (hg19) and comparisons were
conducted between dual reconstituted NSG mice and HIV-1-infected dual
reconstituted NSG mice (unmapped huNSG vs. HIV-huNSG, green color). (E)
Up- and down-regulated human genes in the CC and Hip of HIV-1-infected
dual reconstituted mice compared to controls. Genes with an FDR adjusted P
< 0.05 were graphed.
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Figure 4.3. Biological processes altered by HIV-1 infection. Gene Ontology
(GO) enrichment analysis for gene sets identified as differentially expressed
according to human and mouse data bases in HIV-1 infected humanized mice
and predicted biologic processes.
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Figure 4.4. Production of IFN-β by astrocytes. Levels of human IFN-β were
measured

by

enzyme-linked

immunosorbent

assay

(ELISA)

in

the

supernatants collected from astrocytes (Ast baseline, green), a co-culture of
astrocytes and control monocyte-derived macrophages (Ctl-Ast-MDM, red),
co-culture of astrocytes and HIV-infected macrophages (HIV-Ast-MDM, blue),
HIV-infected

macrophages

(HIV-MDM

baseline,

purple),

and

control

macrophages (Ctl-MDM baseline, orange). X-axis indicates the time points
before (-6 days, -4 days, -2 days) and after co-culture (24 hours, 3 days, 5
days, and 7 days). Data are expressed as the mean of triplicate technical
replicates from one from three independent experiments (each done with
distinct donors). Student t-tests were performed to compare HIV-Ast-MDM to
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Ctl-Ast-MDM for each time point after co-culture. Bars = means ± standard
error of the mean (SEM); **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Figure 4.5. Real-time PCR confirmation of affected human genes in
humanized mice brain tissues. Selected human gene expression profiles in the
CC and Hip were confirmed by TaqMan® real-time PCR. The HIV-1 infected
(n = 6, red symbol) and control group (n = 5, blue symbol) are illustrated. The
fold change in gene expression of human STAT1, STAT2, IRF9, MX1, ISG15,
IFI6, CMPK2, MBP, and ZNF488 between the HIV-1 infected and the control
groups were determined by using the 2−ΔΔCT method (A-I), where ΔCt =
Cttarget – CtGAPDH and Δ(ΔCt) =ΔCtHIV – ΔCtcontrol. Multiple t-tests using
Holm-Sidak method for multiple comparisons correction was applied to
examine significant group differences. Bars = means ± standard error of the
mean (SEM); *P < 0.05.
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Gene Symbol

Cuffdiff_ Cuffdiff_
FC
humanized/
NSG
humanized+
HIV
HIV+/NSG
Up-regulated Genes in Corpus Callosum
AGT
14.46
5.75
2.51
PPOX
9.62
4.99
1.93
GM3893
50.57
31.70
1.60
HBB-BT
62.98
28.83
2.18
COL4A2
11.41
6.85
1.67
Down-regulated Genes in Corpus Callosum
CRYM
2.10
24.89
0.08
FOS
7.85
18.11
0.43
EGR4
7.96
18.14
0.44
ARC
42.47
96.44
0.44
ARC
42.47
96.44
0.44
NR4A3
4.33
9.56
0.45
GPR17
4.28
9.30
0.46
SH3RF2
3.05
6.35
0.48
NR4A1
27.13
55.16
0.49
JUNB
18.35
36.80
0.50
EGR1
55.08
110.39
0.50
FOSL2
6.55
12.80
0.51
E330009J07RiK
8.27
14.96
0.55
EGR3
27.77
50.20
0.55
CTGF
7.59
13.42
0.57
HOMER1
40.59
68.88
0.59
DRD1A
22.25
34.79
0.64
PER1
20.53
31.09
0.66
Up-regulated Genes in Hippocampus
LY6C1
33.18
64.66
1.95
CYSTM1
17.93
34.61
1.93
PVALB
43.07
80.99
1.88
GM3893
17.55
32.87
1.87
DCN
27.02
49.13
1.82
HBB-BT
29.60
53.18
1.80
CDR1
11.96
21.19
1.77
MYL6B
8.54
14.95
1.75
RGS11
12.04
20.53
1.71
GABRA3
14.91
24.72
1.66
GGACT
14.57
24.13
1.66
COX7C
203.55
334.28
1.64

Log2 FDR-adju
FC
sted
P value
1.33
0.95
0.67
1.13
0.74

0.015
0.039
0.015
0.015
0.015

-3.56
-1.21
-1.19
-1.18
-1.18
-1.14
-1.12
-1.06
-1.02
-1.00
-1.00
-0.97
-0.86
-0.85
-0.82
-0.76
-0.65
-0.60

0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.015
0.028
0.015
0.039

0.96
0.95
0.91
0.91
0.86
0.85
0.83
0.81
0.77
0.73
0.73
0.72

0.005
0.033
0.005
0.005
0.005
0.015
0.005
0.044
0.005
0.005
0.036
0.005
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NTSR2
86.62
140.13
ZNHIT2
15.71
25.33
USMG5
381.13
603.23
ATP11B
17.97
28.35
TMSB10
118.08
185.82
CLDN10
34.45
54.13
FKBP1B
23.56
36.42
MT2
193.84
296.45
SERPINI1
55.50
84.08
NRSN1
70.07
105.98
2610203C20RIK
11.98
18.01
SLC25A28
17.05
25.59
RPL39
379.47
568.09
DZIP1
16.48
24.62
AQP4
47.27
70.38
MGST3
85.94
127.68
SLC25A18
45.76
67.81
ID2
54.62
80.92
DDX26B
12.47
18.39
DTNBP1
33.04
48.61
MAP4K2
16.92
24.74
RIAN
139.39
202.44
CLEC2L
25.04
36.37
APPL2
34.53
50.06
ATP5J2
292.23
423.59
A930011O12RIK
45.64
66.00
RPS24
269.31
388.35
HRH3
24.45
35.14
RPL41
848.48
1217.59
C1QA
50.87
72.50
COX7A2
217.13
302.69
Down-regulated Genes in Hippocampus
GPR17
10.45
3.14
C1QL1
11.86
3.95
FOS
9.35
4.12
C1QL2
21.58
10.33
SEMA5A
17.15
8.97
PDYN
13.53
7.15
CASKIN2
8.72
4.63
SOX10
19.36
10.46
ABHD2
25.40
14.14

1.62
1.61
1.58
1.58
1.57
1.57
1.55
1.53
1.51
1.51
1.50
1.50
1.50
1.49
1.49
1.49
1.48
1.48
1.48
1.47
1.46
1.45
1.45
1.45
1.45
1.45
1.44
1.44
1.44
1.43
1.39

0.69
0.69
0.66
0.66
0.65
0.65
0.63
0.61
0.60
0.60
0.59
0.59
0.58
0.58
0.57
0.57
0.57
0.57
0.56
0.56
0.55
0.54
0.54
0.54
0.54
0.53
0.53
0.52
0.52
0.51
0.48

0.005
0.015
0.005
0.005
0.005
0.012
0.036
0.005
0.005
0.005
0.033
0.041
0.005
0.005
0.005
0.020
0.012
0.005
0.017
0.015
0.017
0.027
0.044
0.005
0.017
0.036
0.030
0.033
0.023
0.033
0.027

0.30
0.33
0.44
0.48
0.52
0.53
0.53
0.54
0.56

-1.73
-1.59
-1.18
-1.06
-0.94
-0.92
-0.92
-0.89
-0.85

0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
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KCNG1
PROX1
PAQR9
ADD2
NEUROD1
SLC29A4
ZMAT5
DUSP18
TNR
NPTX1
FRZB
KLHL3
KLF10
NAPEPLD
NR4A3
ERF
SLC8A2
MAL
JPH1
PLCL1
SLIT3
DOC2B
MYCL
POLR2A
NOS1
JUN
TMEFF2
CAMK1D
TMEM178B
EFNB3
LHFPL2
CCND2
SLC44A1
GRIN2B
ORMDL3
IGFBP2
SYNRG
ARC
9830001H06RIK
KBTBD11
SF3A1

16.92
18.99
19.64
47.62
15.21
20.95
60.85
12.57
20.98
224.34
12.51
11.12
11.06
11.43
22.92
14.87
113.05
116.49
12.87
9.31
15.84
27.24
13.32
25.17
11.49
46.65
41.10
57.15
14.37
75.07
12.53
21.85
39.04
11.47
49.03
84.14
19.24
49.28
9.63
36.53
21.44

9.44
10.62
11.04
27.47
8.88
12.27
35.73
7.41
12.53
136.63
7.67
6.84
6.81
7.10
14.28
9.27
70.58
72.92
8.06
5.85
10.03
17.38
8.56
16.19
7.41
30.56
27.04
37.90
9.60
50.18
8.44
14.74
26.34
7.74
33.26
57.15
13.12
33.68
6.61
25.15
14.78

0.56
0.56
0.56
0.58
0.58
0.59
0.59
0.59
0.60
0.61
0.61
0.62
0.62
0.62
0.62
0.62
0.62
0.63
0.63
0.63
0.63
0.64
0.64
0.64
0.64
0.65
0.66
0.66
0.67
0.67
0.67
0.67
0.67
0.68
0.68
0.68
0.68
0.68
0.69
0.69
0.69

-0.84
-0.84
-0.83
-0.79
-0.78
-0.77
-0.77
-0.76
-0.74
-0.72
-0.71
-0.70
-0.70
-0.69
-0.68
-0.68
-0.68
-0.68
-0.68
-0.67
-0.66
-0.65
-0.64
-0.64
-0.63
-0.61
-0.60
-0.59
-0.58
-0.58
-0.57
-0.57
-0.57
-0.57
-0.56
-0.56
-0.55
-0.55
-0.54
-0.54
-0.54

0.005
0.005
0.005
0.005
0.009
0.005
0.005
0.005
0.005
0.005
0.012
0.039
0.012
0.009
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.017
0.005
0.012
0.005
0.005
0.005
0.039
0.005
0.017
0.009
0.012
0.020
0.005
0.020
0.012
0.012
0.009
0.005
0.005
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PNMAL2
SLC7A14
MAG
KCNC3
PLXNA4
FOSL2
FAM163B
DPF1
C1QL3
DOCK10
SYNPR
SOWAHA
SEZ6L
SEZ6L
CAMKK1
RBFOX3
RBFOX3
NEK6
SF3B3
CSNK1D
CSNK1D
ATP8A1
PRPF8
HEXIM1

133.70
30.91
73.06
50.97
19.51
14.06
84.89
28.61
72.48
13.84
62.30
52.84
54.75
54.75
87.63
88.29
88.29
19.70
21.82
63.31
63.31
43.01
40.22
33.50

92.39
21.37
50.58
35.32
13.53
9.76
59.00
20.06
50.87
9.72
43.85
37.49
38.89
38.89
62.29
62.88
62.88
14.04
15.56
45.53
45.53
31.00
29.05
24.23

0.69
0.69
0.69
0.69
0.69
0.69
0.69
0.70
0.70
0.70
0.70
0.71
0.71
0.71
0.71
0.71
0.71
0.71
0.71
0.72
0.72
0.72
0.72
0.72

-0.53
-0.53
-0.53
-0.53
-0.53
-0.53
-0.52
-0.51
-0.51
-0.51
-0.51
-0.50
-0.49
-0.49
-0.49
-0.49
-0.49
-0.49
-0.49
-0.48
-0.48
-0.47
-0.47
-0.47

0.027
0.017
0.015
0.012
0.012
0.015
0.027
0.050
0.025
0.023
0.023
0.033
0.036
0.036
0.017
0.033
0.033
0.046
0.034
0.034
0.034
0.044
0.036
0.046

Table 4.1. Mouse transcriptome affected by humanization and HIV-1 infection
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Gene

Cuffdiff

Cuffdiff_

Symbol

HIV-1

uninfected

Fold
Change

Log2

FDR-adj

FC

usted

(FC)

P value

Up-regulated Genes in the CC
IFN Type I and II Signaling Pathway and Defense Pathways for Viral
Infection
MX1

131.46

9.16

14.36

3.84

0.004

XAF1

40.51

2.88

14.09

3.82

0.004

IFI44L

138.22

11.14

12.41

3.63

0.004

IFIT1

203.88

19.59

10.41

3.38

0.004

IFITM3

759.62

83.51

9.10

3.19

0.004

IFIT3

173.60

19.38

8.96

3.16

0.004

RSAD2

27.92

3.16

8.84

3.14

0.017

IFI6

2043.35

231.66

8.82

3.14

0.004

ISG15

1008.52

119.96

8.41

3.07

0.004

USP18

37.35

5.41

6.90

2.79

0.009

BST2

89.42

13.57

6.59

2.71

0.013

PLSCR1

51.33

8.17

6.28

2.65

0.004

HERC5

36.48

5.94

6.14

2.62

0.004

OAS3

48.03

8.19

5.86

2.55

0.004

STAT1

249.01

72.63

3.43

1.78

0.004

EIF2AK2

59.52

17.61

3.38

1.76

0.004

IFIT5

57.97

17.49

3.31

1.73

0.004

IFIT2

41.82

12.95

3.23

1.69

0.004

IRF9

185.27

65.98

2.81

1.49

0.004

ADAR

115.56

52.32

2.21

1.14

0.004

STAT2

34.46

20.47

1.68

0.75

0.004

Mitochondria RNA Catabolism
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CMPK2

29.17

2.21

13.18

3.72

0.004

PNPT1

23.36

13.54

1.73

0.79

0.004

7.61

4.82

2.27

0.004

Innate Immune Receptor
DDX58

36.69

Associated with IFN Signaling pathway and antiviral response
HERC6

68.08

8.94

7.61

2.93

0.004

DTX3L

26.41

6.63

3.98

1.99

0.004

PARP14

37.21

9.95

3.74

1.90

0.004

PARP9

52.37

14.18

3.69

1.88

0.004

SHISA5

105.47

46.69

2.26

1.18

0.004

PPM1K

49.02

24.16

2.03

1.02

0.004

LAP3

55.17

31.43

1.76

0.81

0.004

Down Regulated Genes in Corpus Callosum
Myelination and Axon Ensheathment
MBP

343.13

1266.74

0.27

-1.88

0.004

MOBP

35.70

124.94

0.29

-1.81

0.004

MAG

16.20

45.68

0.35

-1.50

0.004

PLP1

338.58

889.86

0.38

-1.39

0.004

CLDN11

24.98

64.78

0.39

-1.37

0.004

Nervous System Development
STMN2

14.50

37.20

0.39

-1.36

0.004

ZNF488

11.10

22.15

0.50

-1.00

0.004

IGFBP5

29.92

58.74

0.51

-0.97

0.004

BIN1

26.69

46.21

0.58

-0.79

0.020

APLP1

40.69

64.66

0.63

-0.67

0.030

0.50

-1.00

0.004

Metabolism and Ion Transport
ACBD7

27.01

53.99
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TF

30.65

58.15

0.53

-0.92

0.004

MOXD1

21.09

37.95

0.56

-0.85

0.026

PDDC1

13.83

23.28

0.59

-0.75

0.044

PPP3CB

55.01

83.67

0.66

-0.61

0.009

ALDOC

169.85

252.43

0.67

-0.57

0.047

Cell Cycle Regulation
CDK18

14.38

29.99

0.48

-1.06

0.004

TPPP3

37.02

73.94

0.50

-1.00

0.023

Table 4.2. Differentially expressed human genes in corpus callosum. The
spectrum of Hip up-regulated genes overlapped with that of the CC (Table
4.3).
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Gene
Symbol

FC HIV+/

Cuffdiff_

Cuffdiff_

HIV+

uninfected uninfected

Log2

FDR-adj

FC

usted P
value

Up-regulated Genes in Hippocampus
IFN Type I and II

Signaling Pathway

RSAD2

30.58

1.58

19.38

4.28

0.004

OAS1

56.58

3.70

15.29

3.93

0.004

MX1

127.26

10.10

12.60

3.65

0.004

XAF1

33.61

2.67

12.59

3.65

0.004

ISG15

1253.22

109.74

11.42

3.51

0.004

IFIT3

171.27

16.78

10.21

3.35

0.004

IFIT1

216.92

22.98

9.44

3.24

0.004

IFITM3

799.77

87.99

9.09

3.18

0.004

IFI44L

154.03

17.66

8.72

3.12

0.004

IFI6

2209.14

254.83

8.67

3.12

0.004

USP18

37.89

4.65

8.15

3.03

0.004

BST2

77.68

10.10

7.69

2.94

0.004

PLSCR1

57.33

10.20

5.62

2.49

0.004

IFI35

37.95

7.24

5.24

2.39

0.004

OAS3

42.35

8.28

5.11

2.35

0.004

DDX58

33.66

6.86

4.90

2.29

0.004

IFI44

153.23

33.75

4.54

2.18

0.004

HERC5

35.53

8.84

4.02

2.01

0.004

IFIH1

15.80

3.97

3.98

1.99

0.004

IRF7

15.48

3.94

3.93

1.98

0.008

DDX60

23.62

6.03

3.92

1.97

0.004

TRIM21

14.76

3.91

3.78

1.92

0.008
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DHX58

19.10

5.10

3.75

1.91

0.004

TRIM22

16.17

4.60

3.52

1.81

0.004

IFIT2

36.12

10.84

3.33

1.74

0.004

STAT1

242.18

74.81

3.24

1.69

0.004

IFIT5

54.64

16.88

3.24

1.69

0.004

IRF9

178.46

62.65

2.85

1.51

0.004

HLA-B

107.24

37.75

2.84

1.51

0.004

HLA-C

83.03

29.71

2.80

1.48

0.004

B2M

2577.79

1040.45

2.48

1.31

0.004

EIF2AK2

53.81

21.85

2.46

1.30

0.004

ADAR

115.75

50.99

2.27

1.18

0.004

HLA-A

27.69

12.32

2.25

1.17

0.004

SAMHD1

25.52

12.48

2.05

1.03

0.004

IFI16

26.55

14.46

1.84

0.88

0.004

TRIM62

18.10

10.34

1.75

0.81

0.015

UBE2L6

106.06

62.48

1.70

0.76

0.004

ZC3HAV1

13.54

8.77

1.54

0.63

0.046

STAT2

31.52

20.90

1.51

0.59

0.011

Norepinephrine Metabolic Process
EPAS1

19.27

12.10

1.59

0.67

0.020

LY6E

46.10

11.83

3.90

1.96

0.004

Abnormal Neural Differentiation
PARP10

20.33

3.32

6.12

2.61

0.004

GARS

32.13

19.62

1.64

0.71

0.015

AGRN

41.67

26.44

1.58

0.66

0.004

SOX10

265.68

181.98

1.46

0.55

0.029

Down Regulated Genes in Hippocampus
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MOBP

17.52

59.88

0.29

-1.77

0.006

CLDN11

13.43

31.50

0.43

-1.23

0.006

_SEPT4

7.77

17.54

0.44

-1.17

0.018

C7orf41

15.48

32.09

0.48

-1.05

0.037

C4orf27

15.48

32.09

0.48

-1.05

0.037

MAG

11.75

24.12

0.49

-1.04

0.018

NPAS4

7.54

15.44

0.49

-1.04

0.015

ACBD7

12.59

24.65

0.51

-0.97

0.006

CDK18

9.74

17.44

0.56

-0.84

0.046

JPH3

114.52

203.17

0.56

-0.83

0.035

RPS19

882.33

1561.56

0.57

-0.82

0.040

TF

15.42

26.72

0.58

-0.79

0.035

IGFBP5

18.06

31.14

0.58

-0.79

0.006

FGF13

28.51

45.76

0.62

-0.68

0.049

Table 4.3. Differentially expressed human genes in hippocampus.

124

4.5 Materials and Methods
4.5.1 Animals, cell transplantation, and HIV-1 infection
Newborn NOD/SCID/IL2Rγc−/− (NSG, stock No: 005557, The Jackson
Laboratory, Bar Harbor, ME, USA) mice were bred at the University of
Nebraska Medical Center (UNMC). P0-1 litters were irradiated with 1 Gy (RS
2000 X-ray Irradiator, Rad Source Technologies, Inc., Suwanee, GA, USA).
Pups were intrahepatically injected with 5 × 105 CD34+ HSCs. These mice
were simultaneously transplanted with 1 × 105 NPCs into the right lateral
ventricle. Blood samples collected from the facial vein were evaluated by flow
cytometry starting 8 weeks post-engraftment to monitor expansion of human
leukocytes. Mice with established human hemato-lymphoid reconstitution were
intraperitoneally infected with the macrophage-tropic HIV-1 strain ADA
(HIV-1ADA) and euthanized 6 weeks post infection. Mice characteristics are
listed in Table 3.1. Animal procedures strictly followed the Institutional Animal
Care and Use Committee-approved protocols at UNMC.

4.5.2 Flow cytometry
Blood samples were collected from a facial vein in ethylenediaminetetraacetic
acid (EDTA)-containing tubes (BD Microtainer, Franklin Lakes, NJ, USA) and
centrifuged at 300 g for 5 min. Plasma was stored for HIV viral load
measurements. Blood cells were reconstituted in a buffer of 2% FBS in
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phosphate buffered saline and incubated with antibodies against human cell
markers, including CD45+ fluorescein isothiocyanate (FITC), CD3+ Alexa700,
CD19+ R-phycoerythrin (PE) cyanine 7 (Cy7), CD4+ allophycocyanin (APC),
CD8+ Brilliant VioletTM 450 (BV450), and CD14+ PE for 30 min at 4°C.
Information on all of the antibodies are listed in S3 Table. Samples were
analyzed using a BD LSR2 flow cytometer [182]. Gates were assigned
according to the appropriate control population.

4.5.3 Virus load in plasma, brain, and spleen
Viral RNA copies in the murine plasma were determined by quantitative
real-time polymerase chain reaction (PCR) using a COBAS Amplicor System
v1.5 kit (Roche Molecular Diagnostics, Pleasanton, CA, USA). Spleen and
brain tissue section samples were analyzed for HIV-1 p24 protein staining.
Expression of HIV-1 group-specific antigen (gag) RNA in brain tissues were
analyzed by reverse transcription (RT)-PCR with previously published primers
and probes [192]. Briefly, cortex and striatum from three HIV-infected dual
reconstituted mice and three control dual reconstituted mice were
micro-dissected and transferred to 700 µl QIAzol solution (QIAGEN, Valencia,
CA, USA) for RNA isolation using an RNeasy Mini kit (QIAGEN, Valencia, CA,
USA). A Verso cDNA synthesis kit (Thermo Fisher Scientific, Grand Island,
NY, USA) prepared cDNA according to the manufacturer’s instructions. For the
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first round of conventional PCR, we used the following primers: sense 5’
TCAGCCCAGAAGTAATACCCATGT

3’

and

antisense

5’

TGCTATGTCAGTTCCCCTTGGTTCTCT 3’. The PCR settings were as
follows: 94°C for 3 min, 15 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C
for 1 min. The product of the first PCR was subsequently used as a template in
the second semi-nested real-time PCR amplification performed on the ABI
StepOne Plus real-time PCR machine (Applied Biosystems, MA, USA) using
TaqMan detection chemistry. The primers and probe used for the second PCR
were:

sense

5’

TCAGCCCAGAAGTAATACCCATGT

CACTGTGTTTAGCATGGTGTTT

3’,

and

3’,

antisense

TaqMan

5’

probe

FAM-ATTATCAGAAGGAGCCACCCCACAAGA-TAMRA. The real-time PCR
settings were as follows: 50°C for 2 min, 95°C for 10 min, 45 cycles of 95°C for
15 sec, and 60°C for 1 min. ACH2 cells (8 × 105) containing one integrated
copy of HIV-1 per cell were used in triplicate as standards, with cell and HIV
copy

numbers

ranging

in

serial

10-fold

dilutions

from

105 to

102 deoxyribonucleic acid (DNA) copies/reaction.

4.5.4 Immunohistochemistry
Brain tissue was cut sagittally for both the left and right hemispheres, fixed with
4% paraformaldehyde for 24 hours at 4°C, and then embedded in paraffin.
Paraffin-embedded 5-m thick tissue sections were processed with Declere
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Solution (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s
instructions. Tissue was blocked with 10% normal goat serum in Tris-buffered
saline and 0.05% Tween 20 (TBST) for 45 min and then incubated with mouse
(ms) anti-human GFAP (1:200; Abcam, Cambridge, MA, USA), ms anti-human
nuclear antigen (1:200; Millipore, Billerica, MA, USA), ms anti-human
cytoplasmic marker (1:1000; STEMCELL, Mountain View, Canada), ms
anti-HIV-1 p24 (1:10; Dako, Carpinteria, CA, USA), ms anti-HLA-DR (1:500;
Dako, Carpinteria, CA, USA), ms anti-CD163 (1:50; Thermo Scientific, Denver,
CO, USA), rabbit (rb) anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and rb
anti-human CD4 (1:500; Abcam, Cambridge, MA, USA). Secondary antibodies
were goat anti-ms and goat anti-rb immunoglobulin G (IgG) horseradish
peroxidase (HRP; Dako, Carpinteria, CA, USA). Bright field images were
captured and photographed using 20× and 100× objectives on a Nuance
Multispectral Tissue Imaging system (CRi, Wobum, MA). Immunostained
sections were scanned using a high-resolution scanner (Ventana Medical
Systems, Inc., Oro Valley, AZ, USA). DEFINIENS Tissue Studio® software
(Definiens AG, Munich, Germany) was used to analyze the brain sections
stained for human glial and immune cells. None of human-specific antibodies
had cross-reactivity and stained control non-humanized mouse brain sections.

4.5.5 Immunofluorescence
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For immunofluorescent staining of paraffin-embedded tissue, sections were
processed and blocked as described above. Ms anti-human GFAP (1:200;
Abcam, Cambridge, MA, USA), ms anti-human nuclei (1:200; Millipore,
Billerica, MA, USA), rb anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and
rb anti-Oligo2 (1:500; PhosphoSolutions, Aurora, CO, USA) were applied. For
immunofluorescent characterization of cultivated NPC, ms anti-human GFAP
(1:200; Abcam, Cambridge, MA, USA), ms anti-MAP2 (1:200; Santa Cruz,
Santa Cruz, CA, USA), ms anti-glutamic acid decarboxylase 67 (GAD67;
1:500; Millipore, Billerica, MA, USA), rb anti-nestin (1:200; Millpore, Billerica,
MA, USA), and rb anti-Tuj-1 (1:500; Biolegend, San Diego, CA, USA) were
applied. Secondary antibodies were goat anti-ms IgG Alexa 488 (1:00;
Invitrogen, Grand Island, NY, USA), goat anti-ms IgG Alexa 594 (1:00;
Invitrogen, Grand Island, NY, USA), goat anti-rb IgG Alexa 488 (1:100;
Invitrogen, Grand Island, NY, USA), and goat anti-ms IgG Alexa 594 (1:00;
Invitrogen, Grand Island, NY, USA). A Leica DM6 system (Leica
Microsystems, Wetzlar, Germany) and a Zeiss LSM510 confocal system (Carl
Zeiss

Microscopy

GmbH,

Jena,

Germany)

were

also

used

for

immunofluorescent imaging. The intensity of illumination and the position of
the sub-region on the microscope were consistent across all images.

4.5.6 RNA isolation and next generation sequencing
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Left hemispheres of the reconstituted mouse brains were preserved in
RNALater (Invitrogen, Grand Island, NY, USA). The corpus callosum and
hippocampus from three HIV-infected dual reconstituted mice, three control
dual reconstituted mice, and three non-manipulated NSG mice were
micro-dissected and transferred to 700 µl of QIAzol solution (QIAGEN,
Valencia, CA, USA) for RNA isolation using an RNeasy Mini kit (QIAGEN,
Valencia, CA, USA). After RNA integrity was analyzed, samples were deep
sequenced using 100 bp/read, up to 40 million reads/sample using an Illumina
HiSeq 2500 Sequence Analyzer (Illumina, Inc., San Diego, CA, USA). For both
the hippocampus and corpus callosum, we compared the control samples
(NSG1–3) to the humanized mouse samples (865, 866, 870), and the
humanized mouse samples to the humanized mouse samples with HIV (862,
868, 869). The reads were mapped to the mm10 mouse genome and the
mouse transcriptome. A third comparison was also made whereby humanized
mouse samples (865, 866, 870) were compared with humanized mouse
samples with HIV (862, 868, 869), but mapped to the hg19 human database.
For both tissues, we collected the unmapped reads, which did not map to the
mouse genome, and remapped them to the human genome. This was done in
order to see what human genes were expressed in these tissues. The cuffdiff
algorithm was used to identify differentially expressed genes; all significant
genes were reported with an FDR adjusted p-value of 5% for all cuffdiff
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comparisons. Cuffdiff was specifically used because it normalizes the
expression values and protects against overdispersion so that the values fit
into a normalized bell curve [200]. The number of total reads and alignment
results are shown in S2 Table.

4.5.7 Macrophage and human fetal astrocyte co-culture
Human monocytes were isolated by leukopheresis from HIV-1/2 and hepatitis
seronegative donors. Human monocytes (2 ×105) were seeded in the inserts of
24-well transwell plates with a pore size of 0.4 µm. (Corning Costar, Corning,
NY, USA). Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Grand
Island, NY, USA) with 10% heat-inactivated pooled human serum, 2 mM
L-glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin, and macrophage
colony-stimulating factor (MCSF) enriched conditioned medium maintained at
37°C in a 5% CO2 incubator was used [227]. On day 7, differentiated
monocyte-derived

macrophages

(MDM)

were

infected

with

HIV-1ADA

(multiplicity of infection (MOI) = 0.01) for 12 hours. Infected macrophages were
maintained in the DMEM medium containing 10% heat-inactivated pooled
human serum, 2 mM L-glutamine, 50 µg/ml gentamicin, and 10 µg/ml
ciprofloxacin for another 6 days before the inserts were transferred to wells
with astrocytes at the bottom. Human fetal astrocytes (HFA) were isolated and
cultured from fetal donors as previously described [228]. HFA (5 ×105) were

131

seeded at the bottom of 24-well transwell plates and maintained in DMEM/F12
(Invitrogen, Grand Island, NY, USA) containing 10% FBS and antibiotics.
Supernatants from HIV-1-infected and control MDM cultures were collected at
6 days, 4 days, and 2 days before co-culture of MDM and astrocytes.
Supernatants from the transwell system were collected at 24 hours, 3 days, 5
days, and 7 days after co-culture.

4.5.8 IFN-β enzyme-linked immunosorbent assay (ELISA)
IFN-β was measured in the supernatants of astrocytes (Ast baseline), a
co-culture of astrocytes and control macrophages (Ctl-Ast-MDM), a co-culture
of astrocytes and HIV-infected macrophages (HIV-Ast-MDM), HIV-infected
macrophages (HIV-MDM baseline), and control macrophages (Ctl-MDM
baseline) using the Human IFN-β bioluminescent ELISA kit (InVivoGen, San
Diego, CA, USA) according to the manufacturer’s protocol.

4.5.9 RT-PCR for selected human and mouse transcripts
First-strand cDNA was prepared from corpus callosum and hippocampus
using the same method described above. For both the hippocampus and
corpus callosum, we compared the control humanized mouse samples (865,
866, 870, 871) to the humanized mouse samples with HIV (861, 862, 864, 867,
868, 869). The catalog numbers of all TagMan® real-time PCR assays from
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Life Technologies are as listed below: hu-STAT1 (Hs01013996_m1),
hu-STAT2

(Hs01013123_m1),

(Hs00895609_m1),

hu-IRF9

hu-ISG15

(Hs00196051_m1),

(Hs01921425_s1),

hu-MX1
hu-CMPK2

(Hs01013364_m1), hu-IFI6 (Hs00242571_m1), hu-MBP (Hs00921945_m1),
hu-ZNF488

(Hs00289045_s1),

(Mm00487796_m1),

ms-MBP

hu-GAPDH

(Hs03929097_g1),

(Mm01266402_m1),

ms-MX1

ms-GAPDH

(Mm999999_g1). The real-time PCR settings were as follows: 50°C for 2 min,
95°C for 10 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min. All real-time
assays

were

carried

out

with

an

Applied

Biosystems® StepOnePlus Real-Time PCR Systems. The fold change in
expression of each target gene mRNA relative to GAPDH between the HIV+
group and the control group was determined by using threshold cycle (Ct) and
the 2−ΔΔCT method, where ΔCt = Cttarget – CtGAPDH and Δ(ΔCt) =ΔCtHIV –
ΔCtcontrol.
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CHAPTER - 5
Summary and Further Directions
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5.1 Summary
Despite of the extensive application of potent antiretroviral therapies, HAND
remains prevalent in nearly 30% HIV-infected individuals. The underlying
neuropathology is rapidly evolving in the era of cART. Translational animal
models remain essential for thorough understanding of the patho-biological
mechanism of HAND, and more importantly for investigating HIV reservoirs in
the central nervous system, as comprehensive research cannot be carried out
in a controlled and reproducible manner on humans. Although the non-human
primate models, HIV-infected humanized mouse models have been
characterized extensively for their ability to recapitulate the human immune
response against HIV, and been applied widely to test the efficacy of
therapeutic approaches, they still remain insufficient to assess the complex
neuroimmune crosstalk during chronic HIV infection, and to investigate the
sites where virus hiding behind blood-brain barrier for the eventual goal of viral
eradication. Due to these unmet needs, a new mouse model with combined
human immune system and glia cells reconstitution was proposed to study HIV
neuropathogenesis.
Innovation of the work is highlighted in Chapter 3, we introduced the
development of a dual reconstituted chimeric mouse model contained both a
human

immune

system

and

human

glia

(primarily

astrocyte

and

oligodendrocyte lineage) in the brain. As mentiond above, studies of innate
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glial cell responses after progressive human HIV-1 infection are hindered due
to the paucity of relevant small-animal models of human disease. To overcome
this limitation, we reported a mouse model with dual humanized glial
components in the brain and human immune system in the periphery. We
transplanted newborn NSG mice both with human NPCs and HSCs in the
lateral ventricle and in the liver respectively. Human cells repopulated the
white matter and periventricular mouse brain regions in an anatomically
symmetrical

manner.

These

human

cells

were

later

revealed

by

immunohistochemistry as astrocyte and oligodendrocyte lineages. The highest
level of reconstitution was in corpus callosum and periventricular region
(around 70-80% of total nucleated cells), with relatively low levels in other
regions like frontal cortex, striatum and brain stem (Around 10-20% of total
nucleated cells). RNA sequencing was applied to examine the influence of
human cell engraftment on the mouse transcriptional profile in selected brain
regions. Human glial engraftment induced modest yet extensive transcriptional
changes associated with multiple biological processes, including synaptic
transportation, angiogenesis, and axon growth, ion channel activities,
compared to non-reconstituted mice.
Uniqueness of the study is shown in Chapter 4, where we investigated the
pathological and molecular changes in this dual reconstituted mouse model
after being infected with macrophage-tropic HIV-1ADA. The Immune analyses of
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these HIV-1-infected mice showed meningeal and perivascular infiltration by
human HLA-DR+ cells and surveillance by activated immune cells in brain
tissue. The molecular mechanisms underlying species-specific virus-immune
system-brain tissue interactions were identified by deep RNA sequencing. In
comparison with uninfected mice, infected human glia-containing brain
samples exhibited unique expression of 45 and 56 human genes in the
hippocampus and corpus callosum respectively. These transcriptional
alterations were linked to IFN type 1 and 2 signaling pathways (STAT1, 2,
IRF9, MX1, ISG15, IFI6, CMPK2) and a range of host antiviral responses.
Differentially expressed mouse genes in the hippocampus reflected tissue
remodeling while down-regulated human genes were linked to altered cell
growth, glial cytoskeleton reorganization, oligodendrocyte differentiation and
myelin ensheathment (MBP, MOBP, PLP1, MAG and ZNF488). The results
surprisingly overlapped with the disease profile observed by others in human
HIV-1 encephalitic brains. This new model provided a promising future for
study of human-specific viral-glial interactions and discovery of new
therapeutics targets for HIV-1 nervous system infection.

5.2 Further needed refinements of the dual humanized mice
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Despite several advantages of such a chimeric mouse model in studying HIV
neuropathogenesis and nervous system reservoirs, limitations do exist in
following aspects.
First, similar to other animal models requiring engraftment of donor cell or
tissues, differences in each manipulation and heterogeneity existing
throughout donors and recipients resulted in inconsistencies of human cell
repopulation between animals. These features can confound the interpretation
of glial reactions to viral infections and responses to therapies among each
individual. One practical strategy is to standardize the procedures by utilizing
an automatic stereotaxic injection platform to perform human NPCs
transplantation, instead of manual injection.

Another potential strategy to

overcome this limitation is to utilize the technique of induced-pluripotent stem
cells (iPSCs) to generate homogenous clones of progenitor cells for astrocytes
as introduced in the previous study [229].

Additionally, prudent statistical

analyses are necessary for reaching significant conclusions when using this
model for quantitative research. For instance, when we were analyzing the
number of human astrocytes in infected and control mice, up to 50 animals and
200 tissue samples were analyzed by the non-biased image studio to compare
human astrocyte numbers between groups.
Additionally, productive infection of astrocytes has not been observed in
this in vivo model. Although infection of astrocytes by HIV is highly restricted
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[113], it has been hypothesized astrocytes are potential reservoirs in the CNS.
Future efforts on isolating human astrocytes from the chimeric mouse brain
and examining the viral genome ex vivo utilizing more sensitive methods would
be very helpful in testing the hypothesis. The development of single-cell
resolution sequencing methods is also encouraging in differentiating
astrocyte-specific molecular signatures in response to chronic HIV infection
[230].
Thirdly, considerable work is underway to achieve the goal of human
microglial reconstitution, including identifying the human microglia progenitors
during

primitive

hematopoiesis,

and

to

generating

a

mouse

brain

microenvironment permissive to human microglia survival and development
the reconstitution of human microglia.

5.3 Applications of dual humanized mice model in development of
diagnostic and therapeutics for NeruoAIDS and infections of other
pathogens
There are extensive possibilities for future applications of the dual humanized
mouse model in the development of diagnostic and therapeutic approaches for
NeuroAIDS. As reviewed in the Chapter – 1, the old HIVE model has been
extensively applied to test the delivery system of antiretroviral drugs and
adjunctive therapies. This new model with sustained hematopoiesis and
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human glial components will promote longitudinal studies of the efficacy of
cART in protecting human glial cells. In addition, recent studies reported that
blockage of type-I interferon signaling can restore immune function and reduce
HIV-1 reservoirs in the periphery during chronic infection [231-233]. The
human specific transcriptional profiles revealed in the infected dual humanized
mice brains also raised the concern about the role of type-I IFN signaling in the
CNS HIV infection, whether it is beneficial or detrimental? The future
application of the dual humanized mouse model will help to address this
question.
Besides, the dual humanized mice will be benefit the studies of other
neurotropic pathogens that target astrocytes and neural progenitor lineages,
such as John Cunningham virus (JCV), Human cytomegalovirus (HCMV),
Herpes simplex virus (HSV) et al., regarding their neuropathogenesis, latency,
reactivation in a physiological setting.
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